Genetherapy

CRISPR Technology Highlights Genes That Contribute to the Development of Emphysema and COPD – Boston Medical Center

July 17th, 2022

BOSTON Researchers from the Center for Regenerative Medicine at Boston Medical Center and Boston University School of Medicine used variants of CRISPR to understand the functions of the genes that cause emphysema and chronic obstructive pulmonary disease (COPD). Published in Science Advances, researchers discovered functional consequences by turning off the expression of the gene that contributes to the pathogenesis of these diseases.

This is the first time that CRISPRi and CRISPRa have been applied in human induced pluripotent stem cells to understand the functional role of these genes, says Andrew Wilson, MD, a pulmonologist at Boston Medical Center and associate professor of medicine at Boston University School of Medicine. It gets us closer to understanding how inherited factors help contribute to susceptibility to emphysema.

COPD and emphysema is the third leading cause of death worldwide, creating a significant burden of disease. Emphysema is a complex genetic disease caused by a mutation or variant in a number of genes that contribute to making some individuals more susceptible to disease than others. Genome-wide association studies (GWAS) have implicated variants in or near a growing number of genes, but understanding their functions and how they potentially contribute to the development of COPD and emphysema is quite limited.

There have been no new significant pharmacological agents developed to help treat the large number of patients afflicted with COPD or emphysema worldwide, says Rhiannon Werder, MD, a postdoctoral fellow at the Center for Regenerative Medicine at Boston Medical Center and Boston University School of Medicine. Our hope is that this study will help in the understanding of the genetics of the disease, improve our understanding of how the disease occurs at a cellular level, and support the development of new therapies to treat these conditions.

Researchers devised a system using variants of CRISPR to either turn off expression of a gene of interest using CRISPR interference (CRISPRi) or overexpress a gene of interest using CRISPR activation (CRISPRa) in induced pluripotent stem cells (iPSCs). Researchers grew these cells in a dish and differentiated them to generate cells that reside in the lung. The cell type studied is called the type 2 alveolar epithelial cell, a progenitor cell for the alveolus the alveolus is the part of the lung where gas exchange occurs and is the structure that is damaged in emphysema. So by understanding how GWAS genes affect type 2 cells, researchers can start to understand how these might contribute to diseases that affect these cells, like emphysema.

Once type 2 cells were generated, researchers then used CRISPRi to turn off expression of nine different GWAS genes and analyzed them to see how the cells were affected, especially their ability to proliferate, something that they need to be able to do in response to injury like that which occurs in emphysema. Researchers noticed that turning off one particular gene, desmoplakin (DSP), caused the cells to increase their proliferation and increased their expression of genes associated with cellular maturation. Researchers found that cells in which DSP expression was turned off before smoke exposure turned off expression of cell junction genes to a greater degree than in controls. These were also better at forming new colonies, a measure of progenitor function, than controls. Researchers then looked in mice that had DSP deleted from their lung epithelial cells, compared to control mice with normal DSP. Researchers found that the type 2 cells in the DSP deletion mice were more proliferative following injury, consistent with findings in human iPSC-derived type 2 cells.

DSP appears to modulate the proliferative capacity of type 2 cells at baseline and following injuries that are relevant to human disease, such as smoke exposure. Lower levels of DSP expression increase the proliferative capacity of type 2 cells in the system, potentially making them better able to respond to an injury. In contrast, higher levels of expression as found in cells containing the variant associated with COPD risk by GWAS appear to make the cells less proliferative after smoke exposure, potentially explaining how this gene contributes to disease.

Read the original post:
CRISPR Technology Highlights Genes That Contribute to the Development of Emphysema and COPD - Boston Medical Center

Recommendation and review posted by Bethany Smith

Global Gene Therapy Market to Garner a Revenue of About USD 6 Billion by 2031 by Growing with a CAGR of ~34% During 2022-2031; Market to Grow on…

July 17th, 2022

Kenneth Research

Key Companies Covered in the Global Gene Therapy Market by Kenneth Research are Kineta, Inc., Novartis AG, Amgen Inc., bluebird bio, Inc., Gilead Sciences, Inc., Orchard Therapeutics plc, SIBIONO, Questex, CRISPR Therapeutics, Editas Medicine, and others.

New York, July 13, 2022 (GLOBE NEWSWIRE) -- According to the World Health Organization (WHO), around 10 million deaths, or nearly 1 in 6 deaths, were caused by cancer in 2020, making it the top cause of death globally. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. If found early and appropriately treated, many tumors (30% to 50%) are curable. According to the American Cancer Society (ACS), 1,918,030 new cancer cases and 609,360 cancer deaths are expected in 2022, with lung cancer as the primary cause of death accounting for about 350 of those fatalities daily in the United States.

In recent research titled Global Gene Therapy Market, Kenneth Research provided a brief overview of market elements including growth drivers, restraint factors, current market trends, and potential for future growth. The influence of COVID-19 and its effects on end-users are both thoroughly examined in the market research report, which covers the forecast period, i.e., 2022-2031. In addition, the research study examines the product portfolios and market expansion plans of the principal competitors.In 2020, according to the World Cancer Research Fund (WCRF), there were 18 million new cases of cancer worldwide. 9.3 million of these instances involved men, while 8.8 million involved women. The growth of the global gene therapy market can be attributed on account of the rising prevalence of cancer cases. Also, the adoption of gene therapies for the treatment of cancer is predicted to grow the market further. For instance, at the University of Pennsylvania, the first trial for testing a CRISPR-created cancer medicine was launched in the United States in 2019.CRISPR is a gene-editing-tool, that can modify any DNA segment within the 3 billion letters of the human genome. The global gene therapy market is expected to gather around USD 6 billion in revenue by 2031 and grow with a CAGR of ~34% over the forecast period. Get A Sample Copy of This Report @ https://www.kennethresearch.com/sample-request-10070542

The global gene therapy market is segmented on the basis of region into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. On the back of rapid rising cancer incidence rates, and the availability of high disposable income, the market in North America is predicted to experience significant expansion over the course of the forecast period. For instance, the Cancer Facts & Figures 2021 by the American Cancer Society, the study estimates that 1.9 million new instances of cancer were diagnosed and 608,570 cancer deaths in the United States in 2021. Also, an increase in the demand for gene-therapy-related R&D activities further helps the growth of the market. According to the World Bank Data, the domestic general government healthcare expenditure in the U.S. was 5,552.60 IN 2019 whereas in Canada the domestic general health care expenditure was 3,873.70 in 2019. Thus, a rise in government health care support is expected to expand the gene therapy-related R&D activities and further aid on to improve the market in the region.On the other hand, the global gene therapy market in the Asia Pacific region is anticipated to experience the greatest CAGR throughout the forecast period owing to the growing population in the region and increased approval and availability of gene therapy products. According to the World Bank data, the total population of China was 1.41 billion in 2020 whereas, India had 1.38 billion people in 2020. As the population grows, the likelihood of contracting a disease increases. Additionally, it is anticipated that increased government efforts to upgrade the health care infrastructure and rising healthcare costs in that region are expected to expand the industry. Also, the health care expenditure in Japan in 2019 was 10.74% whereas, in China, the GDP was 5.35%. In addition to that, the domestic general government health expenditure per capita for Japan was 3,846.54 in 2019 and China was 492.72 in 2019. Thus, growing health care expenditure and government support in health care expansion are further expected for the growth of the market in the region.

Browse to access In-depth research report on Gene Therapy Market with detailed charts and figures: https://www.kennethresearch.com/report-details/gene-therapy-market/10070542

The study further incorporates Y-O-Y Growth, demand & supply and forecasts future opportunities in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC[Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia Pacific(China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia Pacific), Middle East and Africa(Israel, GCC[Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of the Middle East and Africa).The global gene therapy market is segmented by indication into cancer, metabolic disorders, eye disorders, cardiovascular diseases, and others. Among that the cancer segment is predicted to hold the largest share over the forecast period. On account of the growing widespread presence of cancer cases, the growth of the market can be accredited. The estimated number of new cases of cancer patients in India was around 11,57,294 cases which had risen to 13,24,413 total cases in 2020. In addition to that, the total number of cancer patients was 1,708,921 in 2018 in the U.S., according to the Centers for Disease Control and Prevention (CDC) which got increased to an estimated rate of 1.8 million new cases in 2020. The statistical studies exhibit an increasingly widespread of the disease worldwide which is expected to drive the growth of the segment. Gene therapies are used to treat a variety of malignancies, including those of the brain, lung, breast, pancreatic, liver, prostate, bladder, head & neck, skin, and ovary. For instance, according to the World Cancer Research Fund (WCRF), the most common cancers around the world were breast and lung cancers, accounting to 12.5% and 12.2% respectively of all new cases that were expected to be diagnosed in 2020. Also, there were 1.9 million new instances of colorectal cancer, accounting for 10.7% of all cancer cases in 2020.

Get a Sample PDF of Global Gene Therapy Market @ https://www.kennethresearch.com/sample-request-10070542

The global gene therapy market is segmented by end-user into pharma & biotech, and academia. Numerous ongoing researches and studies have been conducted in the pharma and biotech sector which is anticipated to account for the growth of the segment. For instance, based on a study by PhRMA, there were 289 gene therapies done in clinical development by biopharmaceutical companies in 2018 which had increased to 362 gene therapies in 2020. Also, 6 diseases were already being treated using gene therapy, whereas 362 cell and gene therapies were in the development stage in 2020. In addition to that, 9 cell or gene therapy products have been approved by U.S. Food and Drug Administration (FDA) as of February 2020; they are used to treat cancer, eye conditions, and uncommon inherited diseases.

The global gene therapy market is also segmented on the basis of technology and application.

Global Gene Therapy Market, Segmentation by Technology:

Global Gene Therapy Market, Segmentation by Application:

Enquiry before Buying This Report @ https://www.kennethresearch.com/sample-request-10070542

Some of the well-known leaders in the global gene therapy market that are included in our report are Kineta, Inc., Orchard Therapeutics plc, SIBIONO, Questex, CRISPR Therapeutics, Editas Medicine, and others.

Browse More Related Reports:

Disposable Syringes Market Segmentation by Type (General/Conventional, Safety, and Pre-Filled Syringes); by Syringe Tip (Luer-Lock, Slip, Eccentric, and Catheter Syringe Tips); by Application (Immunization, and Therapeutic Injections, and Others); by End-User (Hospitals, Diagnostic Laboratories, Blood Banks, Pharmaceutical Companies, and Others)-Global Demand Analysis & Opportunity Outlook 2021-2031

Immunoassays in R&D Market Segmentation by Application (Cancer Research, Infectious Diseases, Autoimmune Diseases, Endocrinology, and Others); by End-Use (Academic Laboratories & Institutions, Biotechnology & Pharmaceutical Companies, and Others); and by Product & Services (Analyzers, Software & Services, and Kits & Reagents)-Global Demand Analysis & Opportunity Outlook 2031

Lancet Market Segmentation by Type (Push Button Safety, Pressure Activated Safety, Personal, and Side Button Safety); by Application (Glucose Testing, Hemoglobin Testing, and Coagulation Testing); and by End Users (Homecare, Hospitals & Clinics, Blood Banks, and Others)-Global Demand Analysis & Opportunity Outlook 2031

Anticholinergic Drugs Market Segmentation by Product Type (Natural, Semi-Synthetic Compound, and Synthetic Compound); by Route of Administration (Parenteral, Topical, and Oral); by Application (Muscle Spasm, Parkinsons Disease, Irritable Bowel Syndrome, Chronic Obstructive Pulmonary Disease, and Overactive Bladder); and by Channel of Distribution (Hospitals, Retail Pharmacies, and Online Pharmacies)-Global Demand Analysis & Opportunity Outlook 2031

Global Vaginal Slings Market Segmentation by End-Use (Clinics, Hospitals, and Ambulatory Surgical Centers); and by Slings Type (Conventional, and Advanced Vaginal Slings)-Demand Analysis & Opportunity Outlook 2031

About Kenneth Research

Kenneth Research is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment, etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.

Contact for more Info:

AJ Daniel

Email: info@kennethresearch.com

U.S. Phone: +1 313 462 0609

Web: https://www.kennethresearch.com/

Here is the original post:
Global Gene Therapy Market to Garner a Revenue of About USD 6 Billion by 2031 by Growing with a CAGR of ~34% During 2022-2031; Market to Grow on...

Recommendation and review posted by Bethany Smith

Did You Need That Hysterectomy? – The Epoch Times

July 17th, 2022

While Cesarean delivery remains the most common surgical procedure among women of reproductive age, hysterectomy isnt far behind, according to Johns Hopkins Medicine. The second most common surgery for women of childbearing age, hysterectomy involves the surgical removal of the womb. It can be performed using three different techniques: vaginal, abdominal, and laparoscopic.

According to the National Womens Health Network, approximately 600,000 hysterectomies are performed each year.

In fact, about one-third of American women will have had a hysterectomy by the age of 60, statesBrigham and Womens Hospital.

However, Dr. Jennifer Lang, an obstetrician-gynecologist and gynecological oncologist based in Los Angeles, believes hysterectomies are over-performed.

I consider removing this particular organ as a very radical and extreme act that should be only proceeded with after a thorough review and trial of every other less extreme option that is out there, Lang, who sees the uterus as a sacred organ that plays a spiritual role in a womans life, told The Epoch Times.

When nonmalignant tumors cause heavy bleeding and pelvic pain, doctors will often recommend a hysterectomy. Without a uterus, a woman no longer experiences painful periods.

Endometriosis is a condition in which uterine tissue extends outside of the uterine walls and attaches to the ovaries, intestines, or fallopian tubes. This can cause severe bleeding and pelvic pain.

Uterine prolapse occurs when the uterus falls out of its normal position due to the weakening of the ligaments. A woman who has a prolapsed uterus often feels pressure in her lower abdomen and may not be able to fully empty her bladder.

In a 2016 study conducted by Duke Cancer Institute, scientists observed that women with the BRCA1 gene were specifically at risk for uterine carcinomas.

Some women who have the BRCA gene elect, after a recommendation from their doctor, to get a prophylactic hysterectomy to reduce their likelihood of developing cancer.

While you may think hysterectomieslike mastectomiesare mostly performed to prevent or treat cancer, only 10 percent of hysterectomies are to treat cervical, endometrial, or ovarian cancer, according to Johns Hopkins Medicine.

The hysterectomy procedure dates all the way to the Middle Ages when it was done in a more barbaric and dangerous way than it is today. They were previously conducted to remove a prolapsed uterus.

Early hysterectomies were performed without anesthesia.

The mortality rate was around 70 percent, according to the journal Clinical Obstetrics and Gynaecology. Women who were lucky enough to survive the operation often died shortly afterward from complications, which ranged from inflammation of the abdominal wall, hemorrhage, and sepsis.

Hysterectomies became safer in the 20th century as the complications decreased with the invention of anesthesia and antibiotics.

The current mortality rate from a hysterectomy is thought to be less than 1 percent, according to the National Womens Health Network. While this may seem reassuring, with 600,000 hysterectomies performed a year in the United States, these numbers suggest that thousands of women die from these operations every year.

A hysterectomy is surgical menopause. Pregnancy isnt possible afterward, and most women need to take hormones for the rest of their lives. That has been an ongoing source of sadness for my friend whom well call Anna. Anna felt she wasnt adequately counseled by the surgeon who removed her womb. Now, in her early 50s, she and her partner are trying to have a baby via surrogacy using donor eggs.

Complications are possible with any type of major surgery. Some of the short-term risks from getting a hysterectomy, according to Stanford Health Care, include allergic reaction to anesthesia, blood clots, blood loss, damage to surrounding organs, and infection.

Dr. Shannon Laughlin-Tommaso, an obstetrician-gynecologist who works at the Mayo Clinic in Rochester, Minnesota, conducted a longitudinal study for more than 20 years. She analyzed more than 2,000 women who had a hysterectomy for benign gynecological diseases.

That study, published in 2018, found that women who had hysterectomies were at increased risk for hypertension, high cholesterol, obesity, and even cardiac abnormalities.

The same sample of women was also analyzed in a separate longitudinal study published in 2019 in the peer-reviewed journal Menopause. Women post-hysterectomy, researchers discovered, were at an increased risk for anxiety and depression.

The risk of depression was even higher for women who underwent a hysterectomy between the ages of 18 and 35.

Laughlin-Tommaso is critical of the procedure. Because women often get a hysterectomy at a young age, knowing the risks associated with the procedure even years later is important, she told a reporter for the Mayo Clinic. Our study shows that removing the uterus may have more effect on physical and mental health than previously thought.

In 2021, the FDA approved the Hominis Surgical System, a new robotically-assisted surgical device (RASD) that can help facilitate transvaginal hysterectomy in certain patients. Because it enables surgeons to perform hysterectomies remotely, without needing to touch the patient, RASD has become an even more common method during COVID, according to Nature Machine Intelligence.

This technique surgeons to use computer-generated software to maneuver surgical instruments through tiny incisions in the patients body to remove the uterus through the vagina, rather than through the abdomen. A video camera is inserted laparoscopically through a small incision in the abdomen so that the instruments inside the patient are visible.

In 2021, the FDA conducted a clinical study of 30 patients undergoing transvaginal hysterectomy using the Hominis Surgical System to test its safety and effectiveness.

Patients ranged in age from 37 to 79 years old. More than half had comorbidities, including high cholesterol, hypertension, and osteoporosis.

According to the FDA, all 30 patients underwent successful hysterectomies via this new technique. Minor complications, such as blood loss and urinary tract infections, occurred.

While this seems promising, the study had several flaws. If the patients procedure didnt have to be converted to a traditional method of hysterectomy, it was considered successful. In addition, study participants were only followed for six weeks after the surgery. Whether they suffered long-term adverse effects is unknown.

But we do know about problems with another robotic hysterectomy method, the da Vinci System, which was cleared for use by the FDA in 2005.

In a 2009 study published in the journal Obstetrics and Gynecology, 510 patients were followed after their procedures were performed with the da Vinci. Twenty-one patients reported dehiscence (opening) of the surgical wound in the vagina. Six of the patients bowels prolapsed transvaginally.

A 2018 investigation by NBC found that in a 10-year period there were more than 20,000 adverse events caused by the da Vinci reported to the FDA.

Of those, 17,000 were device malfunctions, including parts of the device falling off into patients bodies, and 274 were deaths.

NBC also reported that training programs for surgeons to use the da Vinci werent required.

In 2015, Laurie Featherstone received a da Vinci hysterectomy. Weeks after her robotic-assisted operation, excess fluid filled her kidneys. Her ureter and colon had been burned by the device. She will use a colostomy bag for the rest of her life.

Despite her doctors reassurance that the robotic technique would lead to fewer complications, Featherstone now lives with permanent health problems.

I put all my faith in the doctor and didnt ask questions, Featherstone told NBC.

A 2015 study published in the American Journal of Obstetrics and Gynecology revealed that nearly 40 percent of hysterectomies may not be necessary.

This study analyzed the use of alternative treatments prior to a hysterectomy for women with benign conditions. They examined the medical records of 3,397 women who underwent hysterectomies.

Some of the results were shocking:

If these numbers are correct, of the 600,000 hysterectomized women in the United States, some 120,000 didnt need the procedure.

It seems women with benign gynecologic conditions arent being informed of alternative medical and natural treatments. Many doctors offer hysterectomies to women who may not need them without first considering less invasive methods.

Women with uterine fibroids can get a myomectomy, which surgically removes the fibroid while keeping the uterus intact. The Mayo Clinic describes the procedure as involving the removal of fibroids either through an incision in the abdomen or minimally invasive techniques through the belly button or vagina.

Myolysis is another alternative a woman can receive to treat fibroids. A gonadotropin-releasing hormone agonist is first given to decrease the size of the fibroid. The procedure is then performed by inserting a laser fiber or electrode into the fibroid to shrink it.

Women who experience heavy menstrual bleeding can also try endometrial ablation. This is a less invasive procedure that removes the uterine lining via electricity, fluids, cold, or balloon therapy, among others.

According to the NIH, hormone therapy may also be effective in treating endometriosis without needing a hysterectomy.

Dr. Aviva Romm, an integrative family physician who studied at Yale University, encourages her patients to focus on preventing fibroids in the first place and healing endometriosis naturally.

According to Romm, three lifestyle changes are key.

A 2016 study in the Journal of Obstetrics and Gynaecology Research found that a diet rich in cruciferous vegetables and fruits was correlated with reducing uterine fibroids.

An added benefit to eating fresh vegetables is that it can help cure endometriosis, Romm noted in an article, The Natural Approach to Endometriosis: Getting to Your Root Causes.

Consuming an excess amount of milk products causes an increase in estrogen levels. Uterine fibroids thrive in high-estrogen environments. Integrative doctors believe that dairy triggers the inflammatory process associated with endometriosis.

Endocrine-disrupting chemicals, as defined by the Endocrine Society, are substances in the environment, food sources, personal care products, and manufactured products that interfere with the normal function of your bodys endocrine system.

High exposure to these chemicals is known to increase fibroid growth. Everything you can do to reduce your exposure to these chemicals, including drinking out of glass instead of plastic, using chemical-free cosmetics, and eating organic produce, will help, Romm said.

There was a whole generation of obstetricians who were trained to believe that after a woman has reached menopause, her uterus was just an excess object that could cause problems if left inside, Lang said.

As more uterus owners are entering the surgical field, Lang hopes unnecessary hysterectomies will become less common.

Hysterectomies are fueled by the business of medicine and reimbursement for procedures, Lang insisted. Theres money there. Thats the darker side of medicine that we cannot ignore.

Read the original:
Did You Need That Hysterectomy? - The Epoch Times

Recommendation and review posted by Bethany Smith

Faculty Highlights: Recent Awards and Grants – Drexel University

July 17th, 2022

Last term, Drexel University professors were recognized for their scholarly research and prolific academic and professional contributions. This update offers a snapshot of activity courtesy of the Office of the Provost.

Male Pattern Baldness: Causes, warning signs and symptoms, treatment – Hindustan Times

July 17th, 2022

Male Pattern Baldness is also known as Androgenic Alopecia is among the most common causes of hair loss in males which can start at the age of 20-25 years and by the age of 50, half of the males experience partial or complete baldness or hair loss. Yes, its pretty common to lose your hair and almost go bald in your early twenties and as the name indicates, its genetic in nature and affects a lot of young population nowadays.

It is a common form of hair loss seen in men as well as females. Hair is lost in a well defined pattern leading to recession of the frontal hairline, with time leading to baldness. Earlier stages of the disease exhibits thinning of hair, giving the impression of reduced hair density.

This condition is related to genes and male hormones where your genes regulate the male pattern of baldness which acts through hormones therefore, there is a risk that one could inherit a family history. If your father, uncle or grandfather are bald, there's a considerable probability you can't avoid a similar outcome but in rare cases, it might happen that the hair loss is not implicated by hereditary factors but the gene mutation begins from the carrier and might impact the future generation. Such cases are known as sporadic cases.

Causes:

In an interview with HT Lifestyle, Dr B L Jangid , Dermatologist and Hair Transplant Surgeon at SkinQure Clinic in New Delhi's Saket, revealed, Your genes and male sex hormones have a role in male pattern baldness. It is caused by the conversion of testosterone to Dihydrotestosterone (DHT), which shrinks hair follicles and slows hair growth. The growth phase, or anagen, of the hair cycle, which typically lasts between three and six years, is thought to be shortened by DHT to just a few weeks or months. Other causes include:

Hereditary or genetic factors

Aging is the common reason

Loss of essential nutrients & improper diet

Psychological pressure and anxiety.

Hormonal changes during puberty, pregnancy, and menopause

Chronic illnesses or autoimmune diseases

Female problems like PCOS issues

Environmental factors like pollution, dust, etc.

Echoing the same, Dr Shivaani Yadav, MD Dermatologist and Cosmetologist at Medanta Gurgaon and SAYAA MED in Gurgaon, said, AGA is caused by number of factors with main culprit being an androgen - dihydrotestosterone. Increased levels of this androgen in hair follicles leads to shorter cycle of hair growth. This results in shorter and thinner hair, over time leading to baldness. There is also evidence of AGA being related to certain medical conditions such as coronary heart disease, prostate enlargement and disorders of insulin resistance in men and polycystic ovary syndrome in women. Also, stress and dietary insufficiencies may add upto the hairloss.

Warning signs and symptoms:

According to Dr B L Jangid, when the regular cycle of hair development is altered, hair loss results. He said, Most hair remains in a growth phase during the usual hair-growing cycle (known as the anagen phase). Before it falls out and new hair begins to grow in its place, this phase lasts for roughly 4 years. For those suffering from male pattern baldness, due to hormone interruption, it might happen that the hair growth is compromised for 1 or 2 years instead of 4 years and the hair has a much shorter development period before it starts to fall out.

He added, Bald spots and hair loss are the outcomes of this process. It is identified by the hair loss on the top and front of the head, as well as a receding hairline along with hair thinning. You may eventually acquire a bald patch on top of your head that gets larger with time, and the hair on your crown (the top of your head) may also get thinner. Hair loss along the sides and back of your head is typically not a symptom of male pattern baldness.

Treatments:

Dr Shivaani Yadav shared, With the advancement of medical sciences, there are multiple treatment options to treat AGA. Some of the common topical formulations are of minoxidil 2%-10% solutions, combination of minoxidil & finasteride, redensyl solutions and peptides sprays. Oral medicines for the condition should always be advised by your dermatologist. Biotin supplementation along with various essential vitamins and minerals also helps in regularising normal hair growth cycle. Certain in clinic treatment options like PRP (platelet rich plasma) which is an autologous growth serum also gives great results when done on a regular basis. For some, whove lost a substantial amount of their hair, hair transplant is a go to option. Hair transplant is a safe procedure when done by experienced hands and under correct supervision. Also, not to underestimate the role of a happy state of mind as well as a healthy diet.

However, Dr B L Jangid insisted that since male pattern baldness is genetically inherited, it cannot be avoided. He said, When hair loss is still modest, some therapies for male pattern baldness are more effective. Since Male pattern hair loss is divided into 7 stages, asking your doctor for information and guidance as soon as possible is a sensible move if you are concerned about hair loss. Medicines can help in hair growth; baldness can be postponed. It is recommended to visit a board-certified dermatologist who can guide you with the right treatment after diagnosing your hair loss stage. Minoxidil 5% - It is a liquid that can be applied to the areas of the scalp experiencing hair loss twice per day. It boosts scalp blood flow and promotes hair development.

He further suggested, Finasteride 1 MG: You can take one pill of finasteride every day. It functions by lowering hormone levels that contribute to male pattern baldness. The only side effect of this medicine is that even at low doses, it may cause reduced sperm counts in some men. Platelet-rich plasma (PRP): It is an add-on therapy to control hair loss and thinning. Activated plasma high in platelets is injected into a patient's scalp using this non-surgical therapeutic approach to promote hair growth and thickness.

In a few, male patterns baldness is commonly accepted by males as a natural aspect of ageing but some men may find that hair loss impairs their confidence and lifestyle, especially those who start losing their hair at a younger age. Dr B L Jangid concluded, Although we cant completely treat male pattern baldness but certain treatments have high success rates in delaying hair loss and promoting growth and thickness of hair. Your doctor can advise you on the course of treatment that could be most appropriate for you. They can educate you on the possible negative effects of your medications. Therefore, in order to prevent any additional harm, it is absolutely crucial to understand the baldness pattern and to see a hair transplant expert for the right diagnosis and treatment.

Originally posted here:
Male Pattern Baldness: Causes, warning signs and symptoms, treatment - Hindustan Times

Recommendation and review posted by Bethany Smith

Secrecy: A demon of gene therapy’s past bedevils its future – STAT

July 17th, 2022

Twenty-three years ago, the field of gene therapy was bursting with the promise of breakthrough treatments. Then it was almost instantly derailed by the death of an 18-year-old clinical trial volunteer named Jesse Gelsinger after he received a genetically engineered virus that had been developed to treat his rare liver condition.

An FDA investigation revealed that the principal investigator and/or the team running the gene therapy trial at the University of Pennsylvania failed to disclose that before Gelsinger was treated, other patients had experienced alarming side effects and that monkeys administered the same engineered virus had died. The incident, coupled with dangerous outcomes involving other gene therapy treatments, had a chilling effect on the field and investors backed away.

Today, new approaches to gene therapy that include advances driven by CRISPR gene editing tools are raising hopes of a gene therapy revival. There are potential breakthroughs in the pipeline, including treatments for different types of cancer and sickle cell disease.

Im concerned that gene therapy 2.0 is at risk of making the same mistakes that plagued the 1.0 version. Most notably, exciting work to translate gene therapy advances into safe, effective, and commercially viable treatments are at risk of being undermined by a reluctance to share data.

Im not saying that the field is on the verge of something analogous to the tragedy experienced in 1999. But the road to such extremes can be paved with a series of lesser nondisclosures that inhibit the free flow of scientific data essential for assessing potential risks long before treatments are given to people.

I saw an example in May at the annual meeting of the American Society of Gene and Cell Therapy. A presenter was discussing a new approach for using gene therapy to treat a rare genetic disorder called Leber congenital amaurosis that causes blindness in children. The presenter discussed experiments in mice that involved disabling or deleting certain segments of a gene linked to the disorder, and this treatment appeared to at least slow the process of vision loss.

Assessing the safety and effectiveness of this potentially exciting advance requires knowing which regions of the gene were being modified. But when someone in the audience asked for more details, the presenter indicated that the information was proprietary and he would not disclose that. The exasperated questioner pointed out that the presenters approach was all about deleting [a segment of a gene], but you dont say what you are deleting. The response? Silence.

Tinkering with a particular genes function, even when the goal is to stop it from doing harmful things, can be risky. Knowing which region of a gene is being altered is essential for determining if solving one problem might create an even bigger one. For example, I and other scientists are interested in the potential of using CRISPR gene editing tools to disable a gene called nuclear factor erythroid 2-related factor 2 (NRF2), which produces a protein that protects a certain type of lung cancer tumor from the effects of chemotherapy or radiation. But that same gene confers a range of health benefits, such as withstanding toxic insults like nicotine or radiation or heat stress, and a poorly targeted edit might do more harm than good.

I am also regularly seeing a failure to disclose important details, like studies that use several strains of mice in a gene therapy experiment without clarifying which strain was linked to a particular result. That can make it difficult, or even impossible, to conduct a fundamental exercise in science: reproduce the results of other investigators. Reproducibility is a problem across all areas of science. But the stakes are higher in the fragile world of gene therapy, where investigators need to be doing all they can to protect patient safety.

My initial thoughts about the presenter who was loquacious in describing his success with gene therapy for Leber congenital amaurosis but quiet about revealing his methods was simply, If you arent willing to share your full information, dont present at scientific conferences.

I am not against protecting intellectual property or patenting biotechnology advances. Properly used, these strategies help attract investment that accelerates the search for transformative treatments. But researchers shouldnt come to a place where they benefit from everyone else freely sharing their findings but then refuse to reciprocate.

My broader message is that the field of gene therapy was once severely damaged by not sharing data that may have been able to prevent a young man from losing his life. Transparency in gene therapy research which can be accomplished without compromising commercial prospects is vital to success. One high-profile failure would badly hurt the revival of gene therapy; two would send it back into hibernation.

When everyone embraces transparency, all of our projects are likely to advance faster toward safe and effective treatments and everyone wins: scientists, investors and, most importantly, the people who could benefit from gene therapy.

Eric B. Kmiec is the executive director and chief scientific officer of the ChristianaCare Gene Editing Institute in Newark, Del.

Here is the original post:
Secrecy: A demon of gene therapy's past bedevils its future - STAT

Recommendation and review posted by Bethany Smith

The Importance of Patient Centricity in Clinical Research and Cell / Gene Therapy Development – Contract Pharma

July 17th, 2022

Recently, a patient centricity concept has spread across all corners of the healthcare community with a straightforward goal: to improve and save patients lives through innovative and effective drug therapies adapted to patients' individual needs. However, for this concept to truly come to life, it is necessary to count on temperature-controlled supply chain logisticslike CRYOPDP to turn what could be a complex operation into a highly efficient process. This is extremely vital, because a patients life could literally be on the line with every shipment.Patient centricity in the clinical trial community involves meeting the patients where they are.The clinical trial industry is globalising and demands international healthcare logistics partners that can serve its growing and continuously evolving needs. For decades, temperature-controlled logistics experts have operated behind the scenes with patients barely aware of the hard work that went into their medicines journey. Thanks to the Covid-19 vaccine distributions impressive performance and its universal effect on people's health across the globe, it has become apparent to the world just how critical and important a logistics providers mission is for both patients and the industry.The endless pandemic lockdowns meant that patients could not travel to hospital sites for clinical trials due to travel and access restrictions. This led to a seismic shift where sponsors quickly moved to a direct-to-patient model to try to continue trials and keep patient treatments on schedule. As part of our response to this unique situation, CRYOPDP as a specialist in temperature-controlled logistics, with the mission to improve people's healthcare options, had to go further and dive deeper to better understand customers perceptions of the impact of the pandemic and work with them to provide those options.With the patient always at the centre of its business and considering the huge development of decentralised clinical trials, the development and implementation of a new service such as Direct-to-Patientseems to be the most natural evolution for CRYOPDP. We have been offering this turnkey solution completely adapted to patients needs, with the same efficiency and total peace of mind, to the benefit of many customers.This model makes life a lot easier for patients and their families, as they dont have to make multiple trips to a clinic or hospital that is potentially a great distance from their home. It is also beneficial for patients who may be too ill to travel, as well as saves patients time and money.Because of these benefits, the direct-to-patient model has increased clinical trial recruitment by up to 60 percent and helped to maintain patient retention by over 95 percent. Drug developers can also gain access to a larger patient population by onboarding those who are not located near participating hospitals or clinics.Patient centricity becomes more evident with the new generation of cell and gene therapies.From day one, CRYOPDP temperature-controlled logistics solutions have always been essential to improve and save patients lives. But, when speaking about cell and gene therapies in particular, this gains an even more significant meaning.The increase in personalised medicine, advanced therapies, and improved access to healthcare in the developing world are influencing future supply chain solutions development. Cell and gene therapies are enabling the healthcare community to shift the arrow and think about patients in a whole new way.Cell and gene therapies demand rigorous and precise temperature control to ensure that the therapies maintain their viability. And maintaining temperature control calls for flawless implementation and execution.From designing the best transportation route to selecting the correct packaging, every detail is critical to keep product integrity high under all conditions, and for this to happen, the healthcare community can count on CRYOPDP specialists who can meticulously handle the entire supply chain process. We've been supporting the life sciences and healthcare communities and focused on improving patient centricity with innovative temperature-controlled logistics solutions because thinking about the patient and the outcome of our work is what moves and inspires us to be better every day.

In all the geographies of the world that we cover, around 150 countries, we produce an operational performance of 99.96%. And to deliver such operational performance, we count on our employees, the specialists around the globe, to follow our quality standards and protocols in detail, so we can deliver a quality service.

When dealing with patients lives, there is no room for errors. Its all about quality of service making sure that lifesaving samples are distributed on time, within the correct specifications and at the right temperature to ensure the patient's health is never compromised.This commitment has helped CRYOPDP to win numerous industry awards, including Best Clinical Trial Logistics Provider in APAC at the Bioprocessing Excellence Awards 2021 and Most Advanced Healthcare Solution Providers from Europe 2021 by Healthcare Insights Magazine.Our achievements are being recognised across the industry, and as we continue to improve our services for healthcare communities, it will be the end patient that benefits the most.

See the rest here:
The Importance of Patient Centricity in Clinical Research and Cell / Gene Therapy Development - Contract Pharma

Recommendation and review posted by Bethany Smith

Global Gene Therapy Market to Garner a Revenue of About USD 6 Billion by 2031 by Growing with a CAGR of ~34% During 2022-2031 – GlobeNewswire

July 17th, 2022

New York, July 13, 2022 (GLOBE NEWSWIRE) -- According to the World Health Organization (WHO), around 10 million deaths, or nearly 1 in 6 deaths, were caused by cancer in 2020, making it the top cause of death globally. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. If found early and appropriately treated, many tumors (30% to 50%) are curable. According to the American Cancer Society (ACS), 1,918,030 new cancer cases and 609,360 cancer deaths are expected in 2022, with lung cancer as the primary cause of death accounting for about 350 of those fatalities daily in the United States.

In recent research titled Global Gene Therapy Market, Kenneth Research provided a brief overview of market elements including growth drivers, restraint factors, current market trends, and potential for future growth. The influence of COVID-19 and its effects on end-users are both thoroughly examined in the market research report, which covers the forecast period, i.e., 2022-2031. In addition, the research study examines the product portfolios and market expansion plans of the principal competitors.In 2020, according to the World Cancer Research Fund (WCRF), there were 18 million new cases of cancer worldwide. 9.3 million of these instances involved men, while 8.8 million involved women. The growth of the global gene therapy market can be attributed on account of the rising prevalence of cancer cases. Also, the adoption of gene therapies for the treatment of cancer is predicted to grow the market further. For instance, at the University of Pennsylvania, the first trial for testing a CRISPR-created cancer medicine was launched in the United States in 2019.CRISPR is a gene-editing-tool, that can modify any DNA segment within the 3 billion letters of the human genome. The global gene therapy market is expected to gather around USD 6 billion in revenue by 2031 and grow with a CAGR of ~34% over the forecast period. Get A Sample Copy of This Report @ https://www.kennethresearch.com/sample-request-10070542

The global gene therapy market is segmented on the basis of region into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. On the back of rapid rising cancer incidence rates, and the availability of high disposable income, the market in North America is predicted to experience significant expansion over the course of the forecast period. For instance, the Cancer Facts & Figures 2021 by the American Cancer Society, the study estimates that 1.9 million new instances of cancer were diagnosed and 608,570 cancer deaths in the United States in 2021. Also, an increase in the demand for gene-therapy-related R&D activities further helps the growth of the market. According to the World Bank Data, the domestic general government healthcare expenditure in the U.S. was 5,552.60 IN 2019 whereas in Canada the domestic general health care expenditure was 3,873.70 in 2019. Thus, a rise in government health care support is expected to expand the gene therapy-related R&D activities and further aid on to improve the market in the region.On the other hand, the global gene therapy market in the Asia Pacific region is anticipated to experience the greatest CAGR throughout the forecast period owing to the growing population in the region and increased approval and availability of gene therapy products. According to the World Bank data, the total population of China was 1.41 billion in 2020 whereas, India had 1.38 billion people in 2020. As the population grows, the likelihood of contracting a disease increases. Additionally, it is anticipated that increased government efforts to upgrade the health care infrastructure and rising healthcare costs in that region are expected to expand the industry. Also, the health care expenditure in Japan in 2019 was 10.74% whereas, in China, the GDP was 5.35%. In addition to that, the domestic general government health expenditure per capita for Japan was 3,846.54 in 2019 and China was 492.72 in 2019. Thus, growing health care expenditure and government support in health care expansion are further expected for the growth of the market in the region.

Browse to access In-depth research report on Gene Therapy Market with detailed charts and figures: https://www.kennethresearch.com/report-details/gene-therapy-market/10070542

The study further incorporates Y-O-Y Growth, demand & supply and forecasts future opportunities in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC[Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia Pacific(China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia Pacific), Middle East and Africa(Israel, GCC[Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of the Middle East and Africa).The global gene therapy market is segmented by indication into cancer, metabolic disorders, eye disorders, cardiovascular diseases, and others. Among that the cancer segment is predicted to hold the largest share over the forecast period. On account of the growing widespread presence of cancer cases, the growth of the market can be accredited. The estimated number of new cases of cancer patients in India was around 11,57,294 cases which had risen to 13,24,413 total cases in 2020. In addition to that, the total number of cancer patients was 1,708,921 in 2018 in the U.S., according to the Centers for Disease Control and Prevention (CDC) which got increased to an estimated rate of 1.8 million new cases in 2020. The statistical studies exhibit an increasingly widespread of the disease worldwide which is expected to drive the growth of the segment. Gene therapies are used to treat a variety of malignancies, including those of the brain, lung, breast, pancreatic, liver, prostate, bladder, head & neck, skin, and ovary. For instance, according to the World Cancer Research Fund (WCRF), the most common cancers around the world were breast and lung cancers, accounting to 12.5% and 12.2% respectively of all new cases that were expected to be diagnosed in 2020. Also, there were 1.9 million new instances of colorectal cancer, accounting for 10.7% of all cancer cases in 2020.

Get a Sample PDF of Global Gene Therapy Market @ https://www.kennethresearch.com/sample-request-10070542

The global gene therapy market is segmented by end-user into pharma & biotech, and academia. Numerous ongoing researches and studies have been conducted in the pharma and biotech sector which is anticipated to account for the growth of the segment. For instance, based on a study by PhRMA, there were 289 gene therapies done in clinical development by biopharmaceutical companies in 2018 which had increased to 362 gene therapies in 2020. Also, 6 diseases were already being treated using gene therapy, whereas 362 cell and gene therapies were in the development stage in 2020. In addition to that, 9 cell or gene therapy products have been approved by U.S. Food and Drug Administration (FDA) as of February 2020; they are used to treat cancer, eye conditions, and uncommon inherited diseases.

The global gene therapy market is also segmented on the basis of technology and application.

Global Gene Therapy Market, Segmentation by Technology:

Global Gene Therapy Market, Segmentation by Application:

Enquiry before Buying This Report @ https://www.kennethresearch.com/sample-request-10070542

Some of the well-known leaders in the global gene therapy market that are included in our report are Kineta, Inc., Orchard Therapeutics plc, SIBIONO, Questex, CRISPR Therapeutics, Editas Medicine, and others.

Browse More Related Reports:

Disposable Syringes Market Segmentation by Type (General/Conventional, Safety, and Pre-Filled Syringes); by Syringe Tip (Luer-Lock, Slip, Eccentric, and Catheter Syringe Tips); by Application (Immunization, and Therapeutic Injections, and Others); by End-User (Hospitals, Diagnostic Laboratories, Blood Banks, Pharmaceutical Companies, and Others)-Global Demand Analysis & Opportunity Outlook 2021-2031

Immunoassays in R&D Market Segmentation by Application (Cancer Research, Infectious Diseases, Autoimmune Diseases, Endocrinology, and Others); by End-Use (Academic Laboratories & Institutions, Biotechnology & Pharmaceutical Companies, and Others); and by Product & Services (Analyzers, Software & Services, and Kits & Reagents)-Global Demand Analysis & Opportunity Outlook 2031

Lancet Market Segmentation by Type (Push Button Safety, Pressure Activated Safety, Personal, and Side Button Safety); by Application (Glucose Testing, Hemoglobin Testing, and Coagulation Testing); and by End Users (Homecare, Hospitals & Clinics, Blood Banks, and Others)-Global Demand Analysis & Opportunity Outlook 2031

Anticholinergic Drugs Market Segmentation by Product Type (Natural, Semi-Synthetic Compound, and Synthetic Compound); by Route of Administration (Parenteral, Topical, and Oral); by Application (Muscle Spasm, Parkinsons Disease, Irritable Bowel Syndrome, Chronic Obstructive Pulmonary Disease, and Overactive Bladder); and by Channel of Distribution (Hospitals, Retail Pharmacies, and Online Pharmacies)-Global Demand Analysis & Opportunity Outlook 2031

Global Vaginal Slings Market Segmentation by End-Use (Clinics, Hospitals, and Ambulatory Surgical Centers); and by Slings Type (Conventional, and Advanced Vaginal Slings)-Demand Analysis & Opportunity Outlook 2031

About Kenneth Research

Kenneth Research is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment, etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.

Contact for more Info:

AJ Daniel

Email: info@kennethresearch.com

U.S. Phone: +1 313 462 0609

Web: https://www.kennethresearch.com/

View original post here:
Global Gene Therapy Market to Garner a Revenue of About USD 6 Billion by 2031 by Growing with a CAGR of ~34% During 2022-2031 - GlobeNewswire

Recommendation and review posted by Bethany Smith

Solvias Acquires Cergentis to Bolster Biologics and Cell & Gene Therapy Capabilities – PR Newswire

July 17th, 2022

Cergentis is a cornerstone acquisition that expands Solvias' solutions supporting complex and emerging therapies.

According to pharmaceutical market intelligence provider, Evaluate, global sales of cell and gene therapies are projected to accelerate at a 63% compound annual growth rate through 2026. As more researchers leverage emerging genetic engineering techniques to develop complex, novel medicines, they require sophisticated solutions to analyze their safety and effectiveness.

With the addition of Cergentis, Solvias supports the increasing number of global pharmaceutical, biotech, and contract development and manufacturing organizations developing genetically engineered therapies with an expanded platform of testing services highlighted by:

Archie Cullen, CEO, Solvias, stated:"We are relentlessly focused on ensuring the safety of new therapies in development. Cergentis is a cornerstone acquisition that expands our solutions supporting complex and emerging therapies. We will continue to pursue strategic acquisitions that add specialized capabilities to our offering and advance our goal of being a forerunner in our industry."

Joris Schuurmans, CEO, Cergentis, added:"We are excited to become part of a global leader that complements our scientific expertise, innovation and customer service. Solvias and Cergentis share a deep commitment to providing our customers with the highest quality solutions and support to safely get their products into the hands of patients who need them."

Effective immediately, Mr. Schuurmans will join Solvias' leadership team and continue to lead operations for Cergentis.

Cergentis marks Solvias' second acquisition since partnering with health care investors Water Street Healthcare Partners and JLL Partners in 2020. The company has recruited industry leaders to join its board and commenced a program to significantly upgrade and expand its information technology platform and infrastructure to support its plans for global expansion.

Financial terms of the acquisition are not being disclosed. Achelous Partners served as the advisor to Cergentis on the transaction.

About CergentisCergentis is a trusted genomics-focused biotechnology company providing services and in-house solutions based on its proprietary genomic analysis platform to all leading biopharmaceutical companies and renowned research institutes. With widely published and recognized genetic analyses, Cergentis supports a global customer base in the characterization and QC of genetically engineered models, biopharmaceutical cell line development, and cell- and gene therapy products. By helping to de-risk R&D program decisions, minimizing time-to-clinic, providing objective genomic evidence for regulators, and supporting patient safety, Cergentis aims to support biopharmaceutical medicine development programs worldwide. For more information, visit cergentis.com.

About Solvias AGSolvias is a worldwide leader in contract research, development and manufacturing for the pharmaceutical, biotech, material science and cosmetic industries. Drawing on 20 years of scientific excellence, the company provides flexible and scalable analytical and manufacturing solutions that ensure the integrity of pharmaceutical and medical device products across their life cycle. Headquartered in Kaiseraugst near Basel, Switzerland, Solvias and its laboratories operate to the highest standards and in accordance with ISO, GMP, GLP and FDA regulations. For more information, visit solvias.com.

SOURCE Solvias

Original post:
Solvias Acquires Cergentis to Bolster Biologics and Cell & Gene Therapy Capabilities - PR Newswire

Recommendation and review posted by Bethany Smith

GenScript ProBio, DAAN Bio Therapeutics Enter Cell and Gene Therapy Partnership – Contract Pharma

July 17th, 2022

");$(".close-btn").click(function() { $(this).parent().fadeOut(800);});setTimeout(showpanel1, 5000);function showpanel1() { $(".close-btn").css("bottom","79px");}'); } }); } var menu = new cbpTooltipMenu(document.getElementById('cbp-tm-menu')); $(document).ready(function () { if ($(".ad-box").length) { $(".pushhead").addClass("right-space"); } });");$(".close-btn").click(function() { $(this).parent().fadeOut(800);});setTimeout(showpanel1, 5000);function showpanel1() { $(".close-btn").css("bottom","79px");}

Breaking News

Sign MOU for the discovery and development of novel drugs.

07.14.22

Through this agreement, both companies will cooperate in the overall development process, such as discovery, manufacturing and clinical trials of antibody and cell treatments, and related research and service projects.

DAAN Bio Therapeutics has conducted single cell transcriptomic and proteomic biomarker analysis through its own analysis platform using tissues secured from solid cancer patients along with DAAN Cancer Research Institute and Yonsei New Il Han Institute for Integrative Cancer Research.

Accordingly, DAAN Bio Therapeutics signed a contract manufacturing organization (CMO) service through GenScript ProBio to develop antibodies that specifically bind to the discovered target material, and established its own bispecific antibody production pipeline using antibodies derived through GMP production.

I hope this strategic partnership with DAAN Bio Therapeutics will be of great support as a global partner in accelerating the development of DAAN's antibody and cell therapy through the GenScript ProBio's one-stop CDMO service platform, said Brian Min, CEO, GenScript ProBio.

Byoung Chul Cho, co-founder and CEO, DAAN Bio Therapeutics, said, This strategic cooperation will be an opportunity to revitalize the development of antibody and cell therapy that control unique cancer treatment targets secured by DAAN Bio Therapeutics using GenScript ProBio's qualified and competitive technologies.

Through this partnership, both GenScript ProBio and DAAN Bio Therapeutics will continue their cooperation more closely with each other to develop subsequent pipelines of DAAN Bio Therapeutics, such as antibody drug and cell therapy.

See the original post:
GenScript ProBio, DAAN Bio Therapeutics Enter Cell and Gene Therapy Partnership - Contract Pharma

Recommendation and review posted by Bethany Smith

BioMarin Presents Findings from Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the International Society on Thrombosis and…

July 17th, 2022

BioMarin Presents Findings from Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the International Society on Thrombosis and Haemostasis (ISTH) 2022 Congress July 9-12, Including 4 Oral and 2 Poster Presentations

Commitment to Advancing Care for People with Hemophilia A Demonstrated with Largest and Longest, OngoingClinical Development Program for any Gene Therapy in Hemophilia A

European Commission Approval for Valoctocogene Roxaparvovec Expected Q3 2022

SAN RAFAEL, Calif., July 11, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that it presented four oral presentations and two poster presentations on valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, at the International Society on Thrombosis and Haemostasis (ISTH) 2022 World Congress from July 9-12 in London.

"With each passing year, the breadth of data supporting valoctocogene roxaparvovec increasingly demonstrate the positive impact gene therapy treatment may provide people with severe hemophilia A. These presentations at ISTH offer supportive evidence of long-term hemostatic efficacy, consistent safety results in clinical studies, efficacy from our pivotal study that is consistent with propensity scoring, the clearance of the vector, and on health-related quality of life over six years," said Hank Fuchs, M.D., President of Worldwide Research and Development at BioMarin. "We look forward to an anticipated approval of valoctocogene roxaparvovec in Europe and providing a therapy that could represent an important and valuable treatment choice for patients with severe Hemophilia A by offering the potential to reduce both the burden of the disease as well as the burden of treatment."

"BioMarin continues to increase and share important data about investigational valoctocogene roxaparvovec that may be useful for patients and physicians to evaluate therapeutic options based on an individual's unique circumstances," said one of the presenters Professor Johnny Mahlangu, a study investigator and Professor in Haematology and Head of School of Pathology in the Faculty of Health Sciences of the University of the Witwatersrand in Johannesburg, South Africa.

Presentation of these data at ISTH follows the Committee for Medicinal Products for Human Use (CHMP) adopting a positive opinion recommending conditional marketing authorization (CMA) for valoctocogene roxaparvovec for adults with severe hemophilia A. Valoctocogene roxaparvovec is the first gene therapy to be recommended for approval in Europe for hemophilia A. A final approval decision, typically consistent with the CHMP recommendation, is expected from the European Commission in Q3 2022.

BioMarin's presentations at ISTH include:

Oral Presentations

Comparative effectiveness of valoctocogene roxaparvovec and prophylactic factor VIII replacement estimated through propensity scoring

Anthony J. Hatswell, PhD, Director and Analyst, Delta Hat Limited, Nottingham, UK

Sunday July 10, 2022, 3:45 PM - 4:00 PM BST

Relationship between transgene-produced FVIII and bleeding rates 2 years after gene transfer with valoctocogene roxaparvovec: Results from GENEr8-1

Professor Johnny Mahlangu, Professor of Haematology and Head of School of Pathology in the Faculty of Health Sciences of the University of the Witwatersrand in Johannesburg, South Africa.

Sunday July 10, 2022, 3:15 PM - 3:30 PM BST

Hemostatic results for up to 6 years following treatment with valoctocogene roxaparvovec, an AAV5-hFVIII-SQ gene therapy for severe hemophilia A

Professor Michael Laffan, faculty of Medicine, Department of Immunology and Inflammation at Imperial College London, Director of the Hammersmith Hospital Haemophilia Centre

Sunday July 10, 2022, 3:00 PM - 3:15 PM BST

Innate and Adaptive Immune Responses to Adeno-associated viral Gene Therapy in the Severe Hemophilia A Dog Model

Paul Batty, MBBS, PhD, Associate Professor at University College London and an Honorary Consultant in Haemostasis and Thrombosis at the Katharine Dormandy Haemophilia and Thrombosis Centre (Royal Free Hospital, London, UK)

Saturday, July 9, 2022, 2:00 PM 2:15 PM BST

Posters

Comparability of bleeding outcomes by prophylactic FVIII replacement intensity: A post hoc analysis of a noninterventional study of men with severe hemophilia A

Charlotte Camp, MSc, Associate Director, Health Economics and Outcomes Research, BioMarin

Monday July 11, 2022, 6:30 PM - 7:30 PM BST

Blood Biodistribution and Vector Shedding of Valoctocogene Roxaparvovec in People with Severe Hemophilia A: Results from the Phase 3 GENEr8-1 Trial

Suresh Agarwal, PhD, MS, RPh, Director, Clinical Pharmacology, BioMarin

Sunday July 10, 2022, 6:30 PM - 7:30 PM

About Hemophilia A

People living with hemophilia A lack sufficient functioning Factor VIII protein to help their blood clot and are at risk for painful and/or potentially life-threatening bleeds from even modest injuries. Additionally, people with the most severe form of hemophilia A (FVIII levels <1%) often experience painful, spontaneous bleeds into their muscles or joints. Individuals with the most severe form of hemophilia A make up approximately 50 percent of the hemophilia A population. People with hemophilia A with moderate (FVIII 1-5%) or mild (FVIII 5-40%) disease show a much-reduced propensity to bleed. The standard of care for individuals with severe hemophilia A is a prophylactic regimen of replacement Factor VIII infusions administered intravenously up to two to three times per week or 100 to 150 infusions per year. Despite these regimens, many people continue to experience breakthrough bleeds, resulting in progressive and debilitating joint damage, which can have a major impact on their quality of life.

Hemophilia A, also called Factor VIII deficiency or classic hemophilia, is an X-linked genetic disorder caused by missing or defective Factor VIII, a clotting protein. Although it is passed down from parents to children, about 1/3 of cases are caused by a spontaneous mutation, a new mutation that was not inherited. Approximately 1 in 10,000 people have Hemophilia A.

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. For additional information, please visitwww.biomarin.com.

Forward-Looking Statements

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including without limitation, statements about: the data presented at ISTH, including the four oral and two poster presentations, the development of BioMarin's valoctocogene roxaparvovec program generally, the impact of valoctocogene roxaparvovec gene therapy for treating patients with severe hemophilia A, a final approval decision for valoctocogene roxaparvovec, typically consistent with the CHMP recommendation, expected from the European Commission in Q3 2022 and the potential to transform the lives of these patients and the ongoing clinical programs generally. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: results and timing of current and planned preclinical studies and clinical trials of valoctocogene roxaparvovec, including final analysis of the data from these trials and the entire development program, including further assessment of safety events, any potential adverse events observed in the continuing monitoring of the patients in the clinical trials; the content and timing of decisions by the FDA, the EMA and other regulatory authorities; the content and timing of decisions by local and central ethics committees regarding the clinical trials; our ability to successfully manufacture valoctocogene roxaparvovec; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission (SEC), including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 as such factors may be updated by any subsequent reports. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin is a registered trademark of BioMarin Pharmaceutical Inc.

Contacts:

Investors

Media

Traci McCarty

Debra Charlesworth

BioMarin Pharmaceutical Inc.

(415) 455-7558

(415) 455-7451

SOURCE BioMarin Pharmaceutical Inc.

Follow this link:
BioMarin Presents Findings from Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the International Society on Thrombosis and...

Recommendation and review posted by Bethany Smith

Automating the Genomic Medicines of the Future – Bio-IT World

July 17th, 2022

Contributed Commentary by Per Hammer, Cytiva

July 15, 2022 | Historically, the heavily regulated biopharma industry has been slow to adopt new technologies. However, a shift toward automation is vital to ensure that next-generation solutionssuch as cell and gene therapiesare produced at scale.

Less than one in five senior pharma executives strongly believe that frontier technologies, such as artificial intelligence, are widely adopted to support automation and increase the speed of specific processes. With cell therapies approved by global regulatory bodies, it is time to accelerate smart technologies and cell and gene therapy manufacturing.

Todays cell therapy treatments are often made on a small-scale, include manual preparation steps, and are produced for a clinical trial setting. Researchers spend days processing cellular material, monitoring its growth during the expansion phase, and preparing for re-administration to the patient. This process is demonstrated in administering autologous treatments so that every patient receives a unique living drug.

Though the current process is complex, it offers inspiring outcomes. For example, on April 1, 2022, the Food and Drug Administration (FDA) approved Kite Pharmas Yescarta, a chimeric antigen receptor (CAR) T-cell therapy for adult patients with large B-cell lymphoma. This kind of cancer is usually resistant to initial treatment and relapses within one year. With FDA approval, Yescarta (axicabtagene ciloleucel) is now the second-line treatment, a first for an autologous CAR T-cell therapy.

Cell Therapy Enters Mainstream

The exceptional results emerging from cell therapy clinical trials suggest we are entering a new phase of medical treatmentone where we can expect far more from our healthcare interventions than we ever imagined. Following the regulatory approval of autologous CAR T-cell therapies, the global cancer treatment landscape is changing, and the future is bright.

The success of COVID-19 vaccines signaled the arrival of the genomic medicines ageone where we hope to see cell and gene therapies deliver long-term remission and even cures for patients with some of the most complex diseases. According to the Alliance for Regenerative Medicine 2021 Annual Report, nearly 60% of the ongoing regenerative medicine clinical trials studied prevalent diseases by the end of the calendar year. But to get these powerful treatments to those who need them, we must have an automated manufacturing infrastructure that can generate cell therapies to meet increased demand in the coming years.

Saving Time Through Automation

Time is of the utmost importance, as biopharma manufacturing involves patient cells that have limited viability. Manual approaches to cell therapy production are time-consuming, and tasks such as checking cells at regular intervals during expansion are laborious. Another time-draining factor is the workflow and cleaning routines involved in maintaining a safe lab environment.

Automated solutions reduce or remove many of these challenges. After setting up a process, an operator can focus on other things while critical parameters such as temperature, pH level, gas transfer, and flow rates are monitored and controlled without human intervention.

Reducing Risks for Better Results

Manual cell processing solutions are complex, with many checkpoints across isolation, expansion, harvesting, and preservation stages. Unfortunately, each of these steps increases the risk potential. Despite the research teams expertise, there is still a chance that materials could be inadvertently contaminated during numerous open stages.

Additionally, limited process control can lead to difficulties in achieving high reproducibility. An automated modular solution minimizes these risks by bringing multiple steps within a closed, highly regulated, and controlled system.

Improving Manufacturing Efficiency

Changing a manufacturing process requires multiple manual routines and adjustments that must be checked and documented. However, documentation and protocols are less helpful when a customized process is used because they only apply to that specific setup.

Standardization would effectively improve manufacturing efficiency. This approach would ensure that what is learned in one project can be referenced in future work, with data and documentation applicable across different technology applications. A modular chain of connected systems allows for process variation with instruments running in customized configurations. Additionally, having control of an individual instrument leads to the straightforward use of built-in software and sensors.

Automated Manufacturing: The Way Forward for Cell and Gene Therapy

By using automated manufacturing to minimize human interaction, time, and resource requirements, it is possible to increase production speed and lower some risks and costs associated with commercialization.

The industry is ever-changing and adjusting its complex, yet exciting challenges will take some time. However, automation can create a significant advantage over competitors, providing the tools needed to produce cell therapies with the highest levels of safety and efficacy for patients.

Per Hammer has two decades of experience in the biopharma industry, mainly supporting customers in academics through process development and manufacturing. Per joined Cytiva in 2001, taking on several distinct roles in the company. Most recently, he progressed from Product Manager Leader for the Bioprocess Automation and Digital Team to Senior Global Product Manager for the Cell & Gene Therapy Automation and Digital Solutions. He can be reached at per.hammer@cytiva.com.

Read the original:
Automating the Genomic Medicines of the Future - Bio-IT World

Recommendation and review posted by Bethany Smith

Gene Editing Market is Expected to Reach USD 13.77 Billion With CAGR of 18% By Forecast 2027 Says Maximize Market Research (MMR) – Digital Journal

July 17th, 2022

Gene Editing Market Is Expected To Reach USD 13.77 Billion By 2027 At A CAGR Of 18 percent.

Maximize Market Research has published a report on theGene Editing Marketthat provides a detailed analysis for the forecast period of 2022 to 2027.

Gene Editing Market Scope:

The report provides comprehensive market insights for industry stakeholders, including an explanation of complicated market data in simple language, the industrys history and present situation, as well as expected market size and trends. The research investigates all industry categories, with an emphasis on key companies such as market leaders, followers, and new entrants. The paper includes a full PESTLE analysis for each country. A thorough picture of the competitive landscape of major competitors in the Gene Editing market by goods and services, revenue, financial situation, portfolio, growth plans, and geographical presence makes the study an investors guide.

Request Free Sample:@https://www.maximizemarketresearch.com/request-sample/2748

Gene Editing Market Overview:

The prospect of treating genetic abnormalities, infectious illnesses, and cancer via gene editing is promising. Gene editing is a form of genetic modification in which, with the use of a designed nuclease or molecular scissor, DNA is added to, removed from, or replaced in an organisms genome in order to treat a specific condition. These nucleases damage DNA at specified sites in the genome to produce double-strand breaks. Targeted mutations result from the repair of the generated double-stranded breaks by non-homologous end joining or homologous recombination (edits).

Gene Editing Market Dynamics:

Gene-editing technologies ongoing technological breakthroughs are a key element fueling the markets growth. Additionally, government financing is readily available, there is more genomics research underway, and cancer and other genetic illnesses are becoming more common, all of which contribute to the markets growth. The rise of the genome editing market is also aided by the creation of breakthrough diagnostic tools based on CRISPR that help to lessen the negative effects of the COVID-19 pandemic.

However, there are several constraints that limit the markets growth to some extent, including the high cost of genomic equipment and rising worries about the dangers and moral dilemmas related to genome editing. However, the presence of major players in developing nations and applications in various stages of the drug development process are a few variables that soon open up profitable potential for the genome editing industry.

The gene editing market appears to be fragmented because there are numerous major and minor significant players. These market participants look to gain a competitive edge through strategic actions like partnerships, acquisitions, growths, collaborations, and the introduction of new products and technologies. Growing investments in genomics R&D, the prevalence of hereditary diseases and chronic disorders, and rapid advancements in genetic engineering are key factors supporting the market share for gene editing.

The market for genome alteration is hampered by certain problems. It is expected that ethical issues with genetic editing, such as safety and the high cost of gene therapies, may somewhat restrain market growth over the predicted years. Market limitations also are brought about by rigorous regulatory rules and unfavourable public opinions of genetic research.

The leading companies in the gene editing industry may face difficulties due to a number of market-related worries. This includes the price of the available genetic editing tools. The markets potential growth may be constrained by expensive maintenance and treatment expenses for genome alteration therapies and associated treatments, as well as by a lack of infrastructure in medium- and low-income countries.

Gene Editing MarketRegional Insights:

During the forecast period, North America is expected to hold a sizable portion of the worldwide genome editing market. The market in the region is expected to expand in the coming years due to the development of gene therapy in the United States, an increase in the consumption of genetically modified crops, an increase in the prevalence of infectious diseases and cancer, and the accessibility of research grants and funding.

Gene Editing MarketSegmentation:

By Technology:

By Application:

By End User:

Gene Editing Market Key Competitors:

To Get A Copy Of The Sample of the Gene Editing Market, Click Here:@https://www.maximizemarketresearch.com/market-report/gene-editing-market/2748/

About Maximize Market Research:

Maximize Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.

Contact Maximize Market Research:

3rd Floor, Navale IT Park, Phase 2

Pune Banglore Highway, Narhe,

Pune, Maharashtra 411041, India

[emailprotected]

View original post here:
Gene Editing Market is Expected to Reach USD 13.77 Billion With CAGR of 18% By Forecast 2027 Says Maximize Market Research (MMR) - Digital Journal

Recommendation and review posted by Bethany Smith

Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022…

July 17th, 2022

- Study participants had an 81%-98% reduction in annualized anti-VEGF injections and demonstrated continuous aflibercept expression levels through three years

- Mean best-corrected visual acuity and central subfield thickness were maintained or improved in subjects treated with ADVM-022

-The Phase 2 LUNA trial is expected to dose the first subject in the third quarter of 2022 and preliminary data anticipated throughout 2023

REDWOOD CITY, Calif., July 15, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced new data from the OPTIC study treating wet age-related macular degeneration (wet AMD) during the American Society of Retina Specialists (ASRS) 2022 Annual Meeting. New data presented are as of February 24, 2022 and include best-corrected visual acuity (BCVA) and central subfield thickness (CST) maintenance, as well as reduction in CST fluctuation after a single, in-office intravitreal (IVT) injection of ADVM-022, ixoberogene soroparvovec (Ixo-vec), in subjects requiring frequent anti-VEGF injections for their wet AMD.

We are pleased to present our findings on BCVA and CST from the OPTIC trial, establishing that maintenance in both BCVA and CST, as well as a reduction in CST fluctuations, were sustained through at least two years, suggesting the long-term durability of Ixo-vec after a single IVT injection, stated Richard Beckman, M.D., chief medical officer at Adverum Biotechnologies. As several publications have recently highlighted, retinal CST fluctuations over time are associated with poor long-term visual outcomes for patients. The combination of durable maintenance of BCVA and reduced CST fluctuations in subjects who previously required frequent IVT injections further support our belief that Ixo-vec can provide better long-term benefit for wet AMD patients. We are excited by the possibility of extending the treatment benefit for this lifelong disease from the order of months to the order of years.

Data Highlights as of February 24, 2022

We are excited to present these encouraging data, showing continuous and stable aflibercept expression for over three years in our OPTIC trial in subjects with wet AMD, commented Laurent Fischer, M.D., president and chief executive officer at Adverum Biotechnologies. As we recently announced, we completed our IND amendment with the U.S. Food and Drug Administration, received European Medicines Agency PRIME designation, and are preparing to initiate the Phase 2 LUNA trial of Ixo-vec in wet AMD. The LUNA trial was designed after a detailed data review from all 55 participants treated to date with a single ADVM-022 injection. Four new enhanced prophylactic steroid regimens will be evaluated in LUNA with the aim of providing steroid coverage during the period of peak immunogenicity. Our goal is to enhance the safety profile of ADVM-022 while building upon the impressive efficacy profile we continue to see in the OPTIC trial. We plan to dose the first subjects in the third quarter of 2022 and anticipate preliminary data from LUNA throughout 2023 and look forward to providing more detail on the expected timeline once we can assess the pace of enrollment.

The LUNA trial is a multicenter, double-masked, randomized, parallel-group Phase 2 trial evaluating two doses of Ixo-vec, including 2E11 and a new, lower 6x10^10 vg/eye (6E10) dose, in up to 72 patients with wet AMD. The LUNA trial will assess four new enhanced prophylactic steroid regimens, including local steroids and combinations of local and systemic steroids to test the relative contribution of local versus systemic AAV exposure on ocular inflammation. Specific regimens include topical difluprednate (Durezol), IVT Ozurdex, or a combination of either topical Durezol or IVT Ozurdex with oral prednisone.

The trial will randomize the participants equally between the 2E11 and 6E10 Ixo-vec doses across four prophylactic steroid regimens and will be conducted at approximately 40 sites in the U.S. and Europe. The primary endpoints will be similar to the OPTIC trial and focus on mean change in BCVA and CST from baseline to one year, and incidence and severity of adverse events. Other data points will include protein expression of aflibercept starting at 10 weeks and an interim analysis at 26 weeks. The study will also evaluate the effectiveness and tolerability of the prophylactic steroid regimens.

As an investigator in OPTIC, I have observed the potential of ADVM-022 to significantly reduce the treatment burden for my patients with neovascular age-relatedmacular degeneration. In the latest data from the OPTIC trial, we have seen a manageable safety profile, robust aflibercept expression, and sustained anatomical improvements after two years following a single 2E11 dose of ADVM-022, said Dante Pieramici, M.D., partner, California Retina Consultants, and presenter of the data at ASRS. I look forward to participating as a LUNA investigator and building on the efficacy and safety profile in OPTIC with a new, lower 6E10 dose and to determine an optimal prophylactic steroid regimen for patients.

About Wet Age-Related Macular Degeneration

Wet AMD, also known as neovascular AMD or nAMD, is an advanced form of AMD, affecting approximately 10% of patients living with AMD. Wet AMD is a leading cause of blindness in patients over 65 years of age, with a prevalence of approximately 20 million individuals worldwide living with this condition. The incidence of new cases of wet AMD is expected to grow significantly worldwide as populations age. AMD is expected to impact 288 million people worldwide by 2040, with wet AMD accounting for approximately 10% of those cases.

About OPTIC Trial of ADVM-022 in Wet AMD

ADVM-022 is Adverums clinical-stage gene therapy product candidate being developed for the treatment of wet AMD. ADVM-022 utilizes a propriety vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. Unlike other ophthalmic gene therapies that require a surgery to administer the gene therapy under the retina (sub-retinal approach), ADVM-022 has the advantage of being administered as a one-time IVT injection in the office and is designed to deliver long-term efficacy and reduce the burden of frequent anti-VEGF injections, optimize patient compliance, and improve vision outcomes for patients with wet AMD.

The OPTIC trial is designed as a multi-center, open-label, dose-ranging, safety and efficacy trial of ADVM-022 in patients with wet AMD who have demonstrated responsiveness to anti-VEGF treatment. Patients in OPTIC are treatment-experienced, and previously required frequent anti-VEGF injections to manage their wet AMD and to maintain functional vision.

About Adverum Biotechnologies

Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for a number of highly prevalent ocular diseases with the aspiration of developing functional cures for these diseases to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, ixoberogene soroparvovec (Ixo-vec), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit http://www.adverum.com.

Forward-looking Statements

Statements contained in this press release regarding events or results that may occur in the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements regarding Adverums plans to initiate a Phase 2 study in wet AMD to investigate the 2x10^11 vg/eye dose and a lower 6x10^10 vg/eye dose of ADVM-022, as well as new enhanced prophylactic steroid regimens, including local steroids and a combination of local and systemic steroids, planned for the third quarter of 2022, as well as the benefits Adverum expects from this trial, and the timing of preliminary data from the LUNA trial. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including risks inherent to, without limitation: Adverums novel technology, which makes it difficult to predict the timing of commencement and completion of clinical trials; regulatory uncertainties; enrollment uncertainties the results of early clinical trials not always being predictive of future clinical trials and results; and the potential for future complications or side effects in connection with use of ADVM-022. Additional risks and uncertainties facing Adverum are set forth under the caption Risk Factors and elsewhere in Adverums Securities and Exchange Commission (SEC) filings and reports, including Adverums Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 filed with the SEC on May 12, 2022. All forward-looking statements contained in this press release speak only as of the date on which they were made. Adverum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Corporate & Investor Inquiries

Anand ReddiVice President, Head of Corporate Strategy and External Affairs & EngagementAdverum Biotechnologies, Inc.T: 650-649-1358E: areddi@adverum.com

Media

Megan TalonAssociate Director, Corporate CommunicationsAdverum Biotechnologies, Inc.T: 650-649-1006E: mtalon@adverum.com

Read more:
Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022...

Recommendation and review posted by Bethany Smith

Global Osteoarthritis Gene Therapy Market 2022 Industry Growth and Product Scope 2028 Top Players as Medipost, Mundipharma Travel Adventure Cinema -…

July 17th, 2022

According to the latest report by MarketandResearch.biz, titled Global Osteoarthritis Gene Therapy Market from 2022 to 2028, covers reliable and updated information, quantitative and qualitative assessments of industry analysts and key competitors across the industry value chain. The report contains a lot of features of the global Osteoarthritis Gene Therapy industry which includes general market conditions, trends, inclinations, key players, opportunities, and geographical analysis.

This research helps the clients with understanding the global Osteoarthritis Gene Therapy market in terms of its definition, division, market potential, compelling patterns, and the difficulties that the market is facing. The report deeply tracks factors such as growth, limitations, and the planned characteristics of each point related to this market.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketandresearch.biz/sample-request/224119

The report presents decisive clarity towards highlighting the most effective segment that enables heavy revenue flow. Relevant details about other market segments are also discussed in the report to show logical conclusions about the most prominent segments in the global Osteoarthritis Gene Therapy market. The report is divided into various segments such as by-products, applications, and regions which will give a universal view of the market growth.

The well-established players in the global Osteoarthritis Gene Therapy market are:

In market segmentation by types, the report covers:

In market segmentation by applications, the report covers the following uses:

Major regions discussed in the research report of the market include:

ACCESS FULL REPORT: https://www.marketandresearch.biz/report/224119/global-osteoarthritis-gene-therapy-market-growth-status-and-outlook-2021-2027

The pointers covered in the market dynamics are the drivers, restraints, and opportunities which affect the growth of the global Osteoarthritis Gene Therapy market during 2022 to 2028 period. The global regional analysis of the market was conducted and is mentioned in the report. Moreover, all the key pointers are explained briefly on a regional basis. The report also includes Porters Five Forces model to give the competitive scenario of the global Osteoarthritis Gene Therapy market.

The report covers expected revenue growth, potential lucrative opportunities, product ranges, pricing factors, and parameters to confer the emerging and new entrants in the industry with structured market data. The report caters to know the dynamics of the global Osteoarthritis Gene Therapy market opportunities and anticipate change.

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]

Other Related Reports:

https://www.marketwatch.com/press-release/global-smart-flat-tv-market-2022prime-factors-segments-insights-technology-advancement-outlook-and-growth-forecast-up-to-2028-2022-07-13

https://www.marketwatch.com/press-release/global-polyurethane-waterproof-paint-market-2022-regional-overview-product-analysis-growth-elements-and-recent-development-to-2028-2022-07-13

https://www.marketwatch.com/press-release/global-hereditary-angioedema-therapeutic-market-trend-analysis-and-revenue-growth-over-forecast-of-2022-2028-2022-07-13

https://www.marketwatch.com/press-release/global-yttrium-hydroxide-market-2022-growth-analysis-key-stakeholders-regional-outlook-end-user-applicants-by-2028-2022-07-13

https://www.marketwatch.com/press-release/global-xanthan-gum-for-pharmaceutical-market-2022future-trends-swot-analysis-remarkable-growth-and-competitive-landscape-by-2028-2022-07-13

https://www.marketwatch.com/press-release/global-polysomnography-systems-market-2022regional-scope-growth-statistics-demand-and-regional-outlook-2028-2022-07-13

https://www.marketwatch.com/press-release/global-sodium-chlorite-for-metal-surface-treatment-marketrising-demands-size-and-statistics-industry-share-and-precise-outlook-20222028-2022-07-13

https://www.marketwatch.com/press-release/global-language-education-software-market-2022regional-overview-substantial-demand-vendor-landscape-and-trends-by-2028-2022-07-13

https://www.marketwatch.com/press-release/global-wool-insole-market-2022-overview-by-rising-demands-and-precise-outlook-by-2028-2022-07-13

https://www.marketwatch.com/press-release/global-external-cables-and-connectors-market-2022-regional-overview-product-analysis-growth-elements-and-recent-development-to-2028-2022-07-13

Read the original here:
Global Osteoarthritis Gene Therapy Market 2022 Industry Growth and Product Scope 2028 Top Players as Medipost, Mundipharma Travel Adventure Cinema -...

Recommendation and review posted by Bethany Smith

Gene Synthesis Market Registered Substantial CAGR Growth Of 27.0% Forecast to 2029 and Market Is Analyzed By Size, Trends, Analysis, Future Scope,…

July 17th, 2022

Gene Synthesis Market report has a lot of features to offer for Gene Synthesis industry which includes general market conditions, trends, inclinations, key players, opportunities, and geographical analysis. This report emphasizes on changing dynamics, growth-driving factors, restraints, and limitations. It includes a detailed analysis of the Gene Synthesis market in customer requirements, customer preferences, and the competitive landscape of the overall market. This report employs SWOT analysis technique for the assessment of the development of the most remarkable market players. An influential Gene Synthesis market report offers broader perspective of the market place with its comprehensive market insights and analysis.

Gene Synthesis business report makes available an overview of the Gene Synthesis industry which is gaining momentum in the last few years. The market report uses a range of steps for collecting, recording, analysing and interpreting market data to make this report all-inclusive. It also offers an outline of the industry that might promote interest among prospective investors, large corporations and everyday users who could participate in the next big opportunity or make their lives just a little easier. The world class Gene Synthesis report comprises of the list of leading competitors, strategic industry analysis and the insights of key factors influencing the Gene Synthesis industry.

Download Sample [emailprotected] https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-gene-synthesis-market

Data Bridge Market Research analyses that the market is growing with a CAGR of 27.0% in the forecast period and is expected to reach USD 21,156.93 million by 2028. Rising prevalence of infectious diseases demands the novel and advanced gene therapy products, vaccines, personalized medicines among others which can be achieved by using gene sequences, thus acts as driver for the gene synthesis market growth.

Gene synthesisis technique of synthetic biology which is employed for the production or creation of artificial gene under laboratory conditions. Gene synthesis technique is used for creating fusion proteins, molecular cloning or in order to achieve high level of protein expression. Traditionally, molecular cloning techniques used which consumes a lot of time and requires a lot of money investment.

Rise in adoption of gene therapy has enhanced the requirement of rapid gene synthesis products which provides with error free gene sequences in less interval of time and hence acts as driver for the gene synthesis market. The ethical issues associated with genetic engineering lowers the demand of gene constructs having the potential to interfere with organisms genomic composition which is restraining the gene synthesis market growth. Increasing demand of personalized medicines has paved the way for genomic which demands the error free gene sequences in at low cost in less span of time, thus acts as an opportunity for the gene synthesis market. Long approval time for gene synthesizer and products synthesized through these products restrict the product manufacturers to earn potential benefit in the market and impacts the overall market size, hence acts as challenge for the gene synthesis market growth.

Market Players Covered:

Eurofins Genomics, ATG:biosynthetics GmbH, Merck KGaA, Aldevron, Synbio Technologies, Thermo Fisher Scientific Inc, Genscript, General Biosystems, Twist Bioscience, Evonetix, Bio-synthesis Inc, LGC Limited, Eurofins Genomics Blue Heron LLC, Macrogen,Inc, Science Exchange, Inc, Integrated DNA Technologies, Inc, Origene Technologies, INC., Proteo Genix, Biocat GMBH among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Browse Full Report Along With Facts and Figures @https://www.databridgemarketresearch.com/reports/global-gene-synthesis-market

The gene synthesis market is analysed and market size information is provided by the country, product & services, gene type, product type, application, method, end user and distribution channel as referenced above.

The countries covered in the gene synthesis market report are the U.S., Canada and Mexico, U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Turkey, Austria, Ireland, and Rest of Europe, China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines and rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Israel, Egypt and rest of Middle East and Africa, Brazil, Argentina, and rest of South America.

Software and services segment.in North American region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of increasing gene therapy based medications. The software and services segment in Germany is dominating the European market owing to increasing research and development for the gene synthesis used in vaccine preparation. China is leading the growth of the Asia-Pacific market and Software and services segment is dominating in this country due to presence of highest number of gene synthesis providers.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Highlights of TOC:

Chapter 1: Market overview

Chapter 2: Global Gene Synthesis Market

Chapter 3: Regional analysis of the Global Gene Synthesis Market industry

Chapter 4: Gene Synthesis Market segmentation based on types and applications

Chapter 5: Revenue analysis based on types and applications

Chapter 6: Market share

Chapter 7: Competitive Landscape

Chapter 8: Drivers, Restraints, Challenges, and Opportunities

Chapter 9: Gross Margin and Price Analysis

Check Complete Table of Contents with List of Table and Figures @ https://www.databridgemarketresearch.com/toc/?dbmr=global-gene-synthesis-market

Highlights of Following Key Factors of Global Gene Synthesis Market

A detailed description of the companys operations and business divisions

Analysts summarization of the companys business strategy

Progression of key events associated with the company

A list of major products, services and brands of the company

A list of key competitors to the company

A list and contact details of key locations and subsidiaries of the company

The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Browse Related Reports:

Psychedelic Drugs Market Global Trends, Share, Industry Size, Growth, Demand, Opportunities and Forecast By 2029

Proton Therapy Market Growing Impressive Business Opportunities, Industry Trends, Global Demand and Future Scope

Gene Synthesis Market Global Industry Analysis by Size, Demand, Future Trends, Challenges, Growth Opportunities and Key Players | Global Market Expected to Grow at 22.3% CAGR forecast by 2028

Healthcare 3D Printing Market Growth at a Rate of 22.8% & Industry Size, Trends, Growth, Insights and Forecast by 2028

Fitness App Market Global Industry Analysis by Size, Demand, Future Trends, Challenges, Growth Opportunities and Key Players | Global Market Expected to Grow at 25.6% CAGR forecast by 2028

Laboratory Information Management Systems (LIMS) Market Growth at a Rate of 9.3% & Industry Size, Trends, Growth, Insights and Forecast by 2029

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Visit link:
Gene Synthesis Market Registered Substantial CAGR Growth Of 27.0% Forecast to 2029 and Market Is Analyzed By Size, Trends, Analysis, Future Scope,...

Recommendation and review posted by Bethany Smith

Will 100 Million Die From the COVID Vax by 2028? – The Epoch Times

July 17th, 2022

Via this genetic engineering experiment, theyve literally injected seeds of demise into everyday people like a cockroach spray. Based on a 2011 estimate, he believes an extra 700 million will be killed from this bioweapon and theyve known about the risks since 2005.

In this revealing interview with Greg Hunter of USAWatchdog.com, David Martin, Ph.D., presents evidence that COVID-19 injections are not vaccines but bioweapons that are being used as a form of genocide across the global population.1

In March 2022, Martin filed a federal lawsuit against President Biden, the Department of Health and Human Services and the Centers for Medicare and Medicaid Services alleging that COVID-19 shots turn the body into a biological weapons factory, manufacturing spike protein. Not only is the term vaccination misleading when referring to COVID-19 shots, its inaccurate since they are actually a form of gene therapy.2

And we are not only not going to be sued for, you know, any libel or misinformation, we are actually holding people criminally accountable for their domestic terrorism, their crimes against humanity and the story of the coronavirus weaponization that goes back to 1998, Martin says.3

Martin has been in the business of tracking patent applications and approvals since 1998. His company, M-Cam International Innovation Risk Management, is the worlds largest underwriter of intangible assets used in finance in 168 countries. M-Cam has also monitored biological and chemical weapons treaty violations on behalf of the U.S. government, following the anthrax scare in September 2001.4

According to Martin, there are more than 4,000 patents relating to the SARS coronavirus. His company has also done a comprehensive review of the financing of research involving the manipulation of coronaviruses that gave rise to SARS as a subclade of the beta coronavirus family.

Much of the research was funded by the National Institutes of Allergy and Infectious Diseases (NIAID) under the direction of Dr. Anthony Fauci.5Martin explained:6

I think its important for your listeners and viewers to remember that it was 1999 when Anthony Fauci and Ralph Baric at the University of North Carolina Chapel Hill decided to start weaponizing coronavirus they patented in 2002 and you heard that date correctly, thats a year before the SARS outbreak in China.

You know, they knew it was a bioweapon since 2005. They knew it was effective at harming populations, intimidating and coercing populations

According to Martin, the spike protein that the COVID-19 shots manufacture is a computer simulation of a chimera of the spike protein of coronavirus. It is, in fact, not a coronavirus vaccine. It is a spike protein instruction to make the human body produce a toxin, and that toxin has been scheduled as a known biologic agent of concern with respect to biological weapons for the last now decade and a half, he said.7

Rather than being a public health measure as they were widely campaigned to be, COVID-19 shots are an act of bioweapons and bioterrorism. Martin shared that in 2015, Dr. Peter Daszak, head of the EcoHealth Alliance that funneled research dollars from the NIAID to the Wuhan Institute of Virology for coronavirus research, stated:8

We need to increase public understanding of the need for medical countermeasures such as a pan-coronavirus vaccine. A key driver is the media and the economics will follow the hype. We need to use that hype to our advantage, to get to the real issues. Investors will respond if they see profit at the end of the process.

Daszak, who Martin refers to as the money launderer in chief, actually stated that this entire exercise was a campaign of domestic terror to get the public to accept the universal vaccine platform using a known biological weapon. And that is their own words, not my interpretation, Martin said.9

Both Pfizer and Modernas COVID-19 shots contain nucleic acid sequences that are not part of nature and have not been previously introduced to the human body. This amounts to a genetic engineering experiment that did not go through animal studies or clinical trials.

However, already people are dying from the shots and, Martin states, many more will due to issues such as blood clots, damage to the cardiovascular system and problems with liver, kidney and pulmonary function.10

An onslaught of reproductive and cancer cases related to the shots are also anticipated. The fact of the matter is an enormous number of people who are injected are already carrying the seeds of their own demise, Martin said.11As for how many may die, Martin believes the numbers may have been revealed back in 2011, when the World Health Organization announced their decade of vaccination:12

Based on their own 2011 estimate, and this is a chilling estimate, but we just have to put it out there When the Bill and Melinda Gates Foundation, the Chinese CDC, the Jeremy Farrar Wellcome Trust and others published The Decade of Vaccination for the World Health Organization back in 2011 their stated objective was a population reduction of 15% of the worlds population.

Put that in perspective, thats about 700 million people dead and that would put the U.S. participation in that certainly as a pro rata of injected population somewhere between 75 and 100 million people.

When asked what timeframe these people may die in, Martin suggested theres a lot of economic reasons why people hope that its between now and 2028.13This is because of a tiny little glitch on the horizon the projected illiquidity of the Social Security, Medicare and Medicaid programs by 2028.

So the fewer people who are recipients of Social Security, Medicare and Medicaid, the better, Martin said. Not surprisingly, its probably one of the motivations that led to the recommendation that people over the age of 65 were the first ones getting injected.14Other populations at risk are caregivers, including health care providers, and others in the workforce who were forced to be injected, such as pilots.

Why is it that were suddenly having 700 flights a day being canceled because, allegedly, airlines dont have pilots? the dirty secret is there a lot of pilots who are having microvascular problems and clotting problems, and that keeps them out of the cockpit, which is a good place to not have them if theyre going to throw a clot for a stroke or a heart attack,Martin said.

But the problem is were going to start seeing that exact same phenomenon in the health care industry and at a much larger scale, which means we now have, in addition to the problem of the actual morbidity and mortality, meaning people getting sick and people dying.

We actually have that targeting the health care industry writ large, which means we are going to have doctors and nurses who are going to be among the sick and the dead. And that means that the sick and the dying also do not get care.15

Its been stressed by the media and public health officials that COVID-19 shots do not alter DNA. However, Martin brings attention to a little-known grant from the National Science Foundation, known as Darwinian chemical systems,16which involved research to incorporate mRNA into targeted genomes. According to Martin:17

Moderna was started on the back of a 10-year National Science Foundation grant. And that grant was called Darwinian chemical systems the project that gave rise to the Moderna company itself was a project where they were specifically figuring out how to get mRNA to write itself into the genome of whatever target they were going after.

That could be a single-celled organism, it could be a multi-celled organism or it could be a human. And the fact of the matter is Moderna was started on the back of having proven that mRNA can be transfected and write itself into the human genome.

It is completely unknown what the short- or long-term effects of the spike protein analog thats inside people who received COVID-19 injections will be. But with respect to alteration of the genome, Martin states that data show mRNA has the capacity to write into the DNA of humans, and as such, the long-term effects are not going to merely be symptomatic. The long-term effects are going to be the human genome of injected individuals is going to be altered.18

The 2001 anthrax attack, which came out of medical and defense research, led to the passage of the PREP Act, which removed liability for manufacturers of emergency medical countermeasures.

This means that as long as the U.S. is under a state of emergency, things like COVID-19 vaccines are allowed under emergency use authorization. And as long as the emergency use authorization is in effect, the makers of these experimental gene therapies are not financially liable for any harm that comes from their use.

That is, provided theyre vaccines. If these injections are NOT vaccines, then the liability shield falls away, because there is no liability shield for a medical emergency countermeasure that is gene therapy. Further, lawsuits that can prove the companies engaged in fraud will also negate the liability shield. Martin states:19

One of the convenient things about the PREP Act is the immunity shield from liability actually is only as good as the absence of fraud. Because if there was fraud in the promulgation of the events, leading to an emergency use authorization, then all of the immunity shield gets wiped out.

So the reason why it is so important for conversations like the one were having to actually be promoted and be advanced is because the pharmaceutical companies and this includes Pfizer and Moderna and J&J know they are perpetuating a fraud. The great thing about this is when that fraud is established, 100% of the liability flows back to them.

when a fraud was the basis for a fraud, then we actually have a number of other legal remedies that allow you to pierce that veil. So in the end, theres no question and its quite evident based on the current mortality and morbidity data that given the fact that when it comes to biological weapons and bioterror each count comes with $100 million penalty. Thats what the federal statute gives us.

The penalty for corporate domestic terrorism, when you have per count $100 million a pop liabilities that is an existential threat that takes a company like Pfizer or takes a company like Moderna out of existence. And that is what were working for every day.

If youd like to follow the progress of the ongoing legal cases seeking to expose the truth that a criminal organization is seeking to obtain control over the global population via the creation of patented bioweapons marketed as novel viruses and injections you can find all the details at ProsecuteNow.io, a website compiled by Martin and colleagues.20

Originally publishedJuly 16, 2022 on Mercola.com

Views expressed in this article are the opinions of the author and do not necessarily reflect the views of The Epoch Times. Epoch Health welcomes professional discussion and friendly debate. To submit an opinion piece, please follow these guidelines and submit through our form here.

See original here:
Will 100 Million Die From the COVID Vax by 2028? - The Epoch Times

Recommendation and review posted by Bethany Smith

Comparing 4D Molecular Therapeutics (FDMT) and Its Rivals – Defense World

July 17th, 2022

4D Molecular Therapeutics (NASDAQ:FDMT Get Rating) is one of 264 public companies in the Biological products, except diagnostic industry, but how does it weigh in compared to its peers? We will compare 4D Molecular Therapeutics to similar companies based on the strength of its institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

This table compares 4D Molecular Therapeutics and its peers net margins, return on equity and return on assets.

76.6% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 53.5% of shares of all Biological products, except diagnostic companies are owned by institutional investors. 11.2% of 4D Molecular Therapeutics shares are owned by company insiders. Comparatively, 16.4% of shares of all Biological products, except diagnostic companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

4D Molecular Therapeutics peers have higher revenue and earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

This is a summary of current ratings and price targets for 4D Molecular Therapeutics and its peers, as provided by MarketBeat.

4D Molecular Therapeutics presently has a consensus target price of $26.00, suggesting a potential upside of 157.94%. As a group, Biological products, except diagnostic companies have a potential upside of 92.79%. Given 4D Molecular Therapeutics stronger consensus rating and higher possible upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than its peers.

4D Molecular Therapeutics has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics peers have a beta of 0.75, meaning that their average stock price is 25% less volatile than the S&P 500.

4D Molecular Therapeutics beats its peers on 8 of the 13 factors compared.

(Get Rating)

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Link:
Comparing 4D Molecular Therapeutics (FDMT) and Its Rivals - Defense World

Recommendation and review posted by Bethany Smith

Boyle Heights Selected as Host Site for Artificial Intelligence Bootcamp APPLICATIONS NOW OPEN! – GlobeNewswire

July 17th, 2022

BOYLE HEIGHTS, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Global biotherapeutics leader CSL Behring will host a Mark Cuban Foundation Artificial Intelligence (AI) Bootcamp for high school students in the Fall of 2022 in conjunction with the i.am/Angel Foundation. The No Cost AI Bootcamp in Boyle Heights will be targeted at high school students and will introduce underserved students in grades 9 through 12 to basic AI concepts and skills.

CSL Behring is one of 20+ host companies selected to host 30 camps across the US in Fall 2022.

The CSL Behring Bootcamp will be held over four consecutive Saturdays starting on October 22nd and ending on November 12th.

The student and parent application are now open at markcubanai.org/application. Students do not need any prior experience with computer science, programming, or robotics to apply and attend.

Throughout the AI Bootcamp, students will learn what artificial intelligence is and is not, where they already interact with AI in their own lives, and the ethical implications of AI systems including but not limited to TikTok recommendations, smart home assistants, facial recognition, and self-driving cars to name a few.

Students will benefit from volunteer mentor instructors who are knowledgeable about data science and able to help students quickly understand material normally taught at a collegiate level. As part of the 5-hour curriculum, students also get to work in Microsoft Azure, Microsoft's cloud computing platform, each day to build their own AI applications related to Chatbots, Computer Vision, Machine Learning, and Natural Language Processing.

The Mark Cuban Foundation provides the bootcamps curriculum materials, trains volunteer mentors, and recruits and selects local students to attend camp. In addition, the Mark Cuban Foundation and CSL Behring work together to provide food, transportation, and access to laptops for students at no cost throughout the duration of Bootcamp.

"This bootcamp was a great experience and opened my eyes to the multitude of ways that AI can be used. Would definitely recommend it!" - Nhaomi L., CSL Behring 2021

Founded by Mark Cuban in 2019, the AI Bootcamp initiative has hosted free AI bootcamps for students across several US cities, including Dallas, Pasadena, Chicago, Pittsburgh, Detroit, and Atlantic City to name a few. The Mark Cuban Foundation has impacted 450+ students to date and has a goal to have 1,000 students graduate from AI Bootcamps Program in 2023.

CSL Behring develops and delivers innovative therapies for people living with rare and serious conditions. The companys global cell & gene therapy research hub is located in nearby Pasadena.

Students interested in applying to the Mark Cuban Foundation AI Bootcamp should do so before Thursday, September 1st, 2022 at markcubanai.org/application. To see our 2022 camp locations and to learn more about the Mark Cuban Foundation AI Bootcamps, please visit markcubanai.org/faq.

Contact: Carli Lidiak, Mark Cuban FoundationPhone: 309-840-0348Email: carli.lidiak@markcubanai.org

See more here:
Boyle Heights Selected as Host Site for Artificial Intelligence Bootcamp APPLICATIONS NOW OPEN! - GlobeNewswire

Recommendation and review posted by Bethany Smith

Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis – Nature.com

July 17th, 2022

Zhang, L. & Vijg, J. Somatic mutagenesis in mammals and its implications for human disease and aging. Annu. Rev. Genet. 52, 397419 (2018).

CAS PubMed PubMed Central Article Google Scholar

Martincorena, I. & Campbell, P. J. Somatic mutation in cancer and normal cells. Science 349, 14831489 (2015).

CAS PubMed Article Google Scholar

Kakiuchi, N. & Ogawa, S. Clonal expansion in non-cancer tissues. Nat. Rev. Cancer 21, 239256 (2021).

CAS PubMed Article Google Scholar

Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 24772487 (2014).

PubMed PubMed Central Article CAS Google Scholar

Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 24882498 (2014).

PubMed PubMed Central Article CAS Google Scholar

McKerrell, T. et al. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Rep. 10, 12391245 (2015).

CAS PubMed PubMed Central Article Google Scholar

Xie, M. et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat. Med. 20, 14721478 (2014).

CAS PubMed PubMed Central Article Google Scholar

Abelson, S. et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature 559, 400404 (2018).

CAS PubMed PubMed Central Article Google Scholar

Desai, P. et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat. Med. 24, 10151023 (2018).

CAS PubMed PubMed Central Article Google Scholar

Jaiswal, S. et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N. Engl. J. Med. 377, 111121 (2017).

PubMed PubMed Central Article Google Scholar

Dorsheimer, L. et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol. 4, 2533 (2019).

PubMed Article Google Scholar

Jaiswal, S. & Ebert, B. L. Clonal hematopoiesis in human aging and disease. Science 366, eaan4673 (2019).

CAS PubMed PubMed Central Article Google Scholar

Coombs, C. C. et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell 21, 374382.e4 (2017).

CAS PubMed PubMed Central Article Google Scholar

Gibson, C. J. et al. Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. J. Clin. Oncol. 35, 15981605 (2017).

CAS PubMed PubMed Central Article Google Scholar

Meisel, M. et al. Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 557, 580584 (2018).

CAS PubMed PubMed Central Article Google Scholar

Yoshizato, T. et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N. Engl. J. Med. 373, 3547 (2015).

CAS PubMed PubMed Central Article Google Scholar

Bick, A. G. et al. Inherited causes of clonal haematopoiesis in 97,691 whole genomes. Nature 586, 763768 (2020).

CAS PubMed PubMed Central Article Google Scholar

Hinds, D. A. et al. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. Blood 128, 11211128 (2016).

CAS PubMed PubMed Central Article Google Scholar

Szustakowski, J. D. et al. Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank. Nat. Genet. 53, 942948 (2021).

CAS PubMed Article Google Scholar

Fabre, M. A. et al. The longitudinal dynamics and natural history of clonal haematopoiesis. Nature 606, 335342 (2022).

CAS PubMed PubMed Central Article Google Scholar

De-Morgan, A., Meggendorfer, M., Haferlach, C. & Shlush, L. Male predominance in AML is associated with specific preleukemic mutations. Leukemia 35, 867870 (2021).

PubMed Article Google Scholar

Bick, A. G. et al. Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis. Circulation 141, 124131 (2020).

CAS PubMed Article Google Scholar

Bulik-Sullivan, B. K. et al. LD score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat. Genet. 47, 291295 (2015).

CAS PubMed PubMed Central Article Google Scholar

Finucane, H. K. et al. Partitioning heritability by functional annotation using genome-wide association summary statistics. Nat. Genet. 47, 12281235 (2015).

CAS PubMed PubMed Central Article Google Scholar

Corces, M. R. et al. Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. Nat. Genet. 48, 11931203 (2016).

CAS PubMed PubMed Central Article Google Scholar

Finucane, H. K. et al. Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types. Nat. Genet. 50, 621629 (2018).

CAS PubMed PubMed Central Article Google Scholar

Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. Nat. Genet. 44, 369375 (2012) .

CAS PubMed PubMed Central Article Google Scholar

Walsh, T. G. et al. Loss of the exocyst complex component EXOC3 promotes hemostasis and accelerates arterial thrombosis. Blood Adv. 5, 674686 (2021).

CAS PubMed PubMed Central Article Google Scholar

Astle, W. J. et al. The allelic landscape of human blood cell trait variation and links to common complex disease. Cell 167, 14151429.e19 (2016).

CAS PubMed PubMed Central Article Google Scholar

Ning, Z., Pawitan, Y. & Shen, X. High-definition likelihood inference of genetic correlations across human complex traits. Nat. Genet. 52, 859864 (2020).

CAS PubMed Article Google Scholar

Zekavat, S. M. et al. Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection. Nat. Med. 27, 10121024 (2021).

CAS PubMed PubMed Central Article Google Scholar

Niroula, A. et al. Distinction of lymphoid and myeloid clonal hematopoiesis. Nat. Med. 27, 19211927 (2021).

CAS PubMed PubMed Central Article Google Scholar

Kamat, M. A. et al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. Bioinformatics 35, 48514853 (2019).

CAS PubMed PubMed Central Article Google Scholar

Staley, J. R. et al. PhenoScanner: a database of human genotype-phenotype associations. Bioinformatics 32, 32073209 (2016).

CAS PubMed PubMed Central Article Google Scholar

Vsa, U. et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat. Genet. 53, 13001310 (2021).

PubMed PubMed Central Article CAS Google Scholar

Zhu, Z. et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat. Genet. 48, 481487 (2016).

CAS PubMed Article Google Scholar

Ragu, C. et al. The transcription factor Srf regulates hematopoietic stem cell adhesion. Blood 116, 44644473 (2010).

CAS PubMed Article Google Scholar

Zink, F. et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood 130, 742752 (2017).

CAS PubMed PubMed Central Article Google Scholar

Zhou, G. et al. NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis. Nucleic Acids Res. 47, W234W241 (2019).

CAS PubMed PubMed Central Article Google Scholar

Cowen, L., Ideker, T., Raphael, B. J. & Sharan, R. Network propagation: a universal amplifier of genetic associations. Nat. Rev. Genet. 18, 551562 (2017).

CAS PubMed Article Google Scholar

Fernndez-Tajes, J. et al. Developing a network view of type 2 diabetes risk pathways through integration of genetic, genomic and functional data. Genome Med. 11, 19 (2019).

PubMed PubMed Central Article Google Scholar

Tischkowitz, M. et al. Bi-allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia. Br. J. Haematol. 123, 469471 (2003).

CAS PubMed Article Google Scholar

Lim, Y. et al. Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia. Sci. Transl. Med. 7, 291ra96 (2015).

PubMed PubMed Central Article CAS Google Scholar

Ostrander, E. L. et al. The GNASR201C mutation associated with clonal hematopoiesis supports transplantable hematopoietic stem cell activity. Exp. Hematol. 57, 1420 (2018).

CAS PubMed Article Google Scholar

Ghoussaini, M. et al. Open Targets Genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics. Nucleic Acids Res. 49, D1311D1320 (2021).

CAS PubMed Article Google Scholar

Taylor, K. E., Ansel, K. M., Marson, A., Criswell, L. A. & Farh, K. K.-H. PICS2: next-generation fine mapping via probabilistic identification of causal SNPs. Bioinformatics 37, 30043007 (2021).

CAS PubMed Central Article Google Scholar

Farh, K. K.-H. et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 518, 337343 (2015).

CAS PubMed Article Google Scholar

Bao, E. L. et al. Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells. Nature 586, 769775 (2020).

CAS PubMed PubMed Central Article Google Scholar

Buenrostro, J. D. et al. Integrated single-cell analysis maps the continuous regulatory landscape of human hematopoietic differentiation. Cell 173, 15351548.e16 (2018).

CAS PubMed PubMed Central Article Google Scholar

Ulirsch, J. C. et al. Interrogation of human hematopoiesis at single-cell and single-variant resolution. Nat. Genet. 51, 683693 (2019).

CAS PubMed PubMed Central Article Google Scholar

Go here to read the rest:
Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis - Nature.com

Recommendation and review posted by Bethany Smith

How Parents ‘Guarantee’ Baby’s Gender’ Using the Babydust Conception Hack – Newsweek

July 17th, 2022

Discovering the sex of your baby can be one of the most exciting parts of your pregnancy. But what if someone said you could determine your baby's sex when you're trying to conceive?

Kathryn Taylor, author of The Babydust Method: A Guide to Conceiving a Girl or a Boy, has suggested that the timing and frequency of intercourse in relation to ovulation can be used as a sex selection method.

[There is no blah blah] To find out more, Newsweek has spoken to Taylor, fertility and gynecology experts, and parents who have tried the method.

Taylor told Newsweek that the Babydust method relies on factors that may affect whether an X chromosome or Y chromosome sperm fertilizes an egg. The three key components are timing, frequency and, most importantly, monitoring your luteinizing hormone (LH) levels, she added.

"I was my own first test subject," Taylor said. "I had a son first and a daughter second, just as I had planned. Then I tested it on family and friends and was nearly 100% successful."

Taylor recommends that women monitor their LH levels using basic test strips at least twice a dayideally once in the morning and once in the eveningfor three menstrual cycles before they try to conceive. At major online retailers, a pack of 100 basic LH test strips costs around $35.

She said taking these tests would help determine when your LH levels are surging, which typically occurs approximately 24 hours prior to ovulation. By testing from the fifth day of your cycle until you record a "positive" LH surge for three consecutive months, you will have a better chance of predicting your next ovulation.

The Babydust method, having sexual intercourse once two-to-three days prior to ovulation will likely result in conceiving a baby girl. Alternatively, having sex twice - once on the day of your ovulation and the second time approximately 24 hours after - will likely result in a baby boy.

The difference between frequency is based on studies that Taylor references in the book that revealed that "two acts of intercourse 24 hours apart will alter the uterine environment in favor of Y sperm."

According to Taylor, based on the reported "sways" shared by real couples, "the success rate has been consistently at 87% for both girl and boy sways over the past 5 years."

"Every result that is reported is evaluated to make sure the couple followed the method perfectly," she reassured .

Taylor believes that "some couples have said that this method has actually helped them conceive faster." She explained that by regularly monitoring their LH levels, couples are aware of the woman's most fertile days, which helps them time intercourse accordingly and "focus their efforts on the right days."

With that in mind, Taylor emphasized that "this method is not a guarantee," advising couples "to go into this with a positive attitude." "If they keep in mind that the Babydust method is a way to increase your chances, then it lessens the possible disappointment," she suggested.

Antoine Abu Musa, chief medical officer at online IVF clinic NOW-fertility, shared that although the timing and frequency of intercourse have been widely considered as key factors of sex selection, "there is no scientific objective evidence that it works."

Interestingly, Abu Musa suggested that maternal hormonal levels on the day of fertilization can play a role in determining the sex of the embryo. "More females at birth have been associated with various forms of stressful events and circumstances during or prior to pregnancy," he told Newsweek. "Unfortunately, the research in this field is limited and sometimes contradictory," he added.

Abu Masa also believes that ovulation days differ each month and that monitoring ovulation for three months before applying the Babydust method might not be helpful in predicting your future ovulation. He also shared that even after tracking LH levels for three cycles, timing and limiting the intercourse to a certain day of the cycle "might lead to missing the window of fertilization" altogether.

According to Abu Masa, the only reliable and accurate method of sex selection is the PGT-A, a genetic test performed on embryos fertilized through invitro fertilization (IVF). Dr. Zev Williams of Columbia University Fertility Center suggested that this approach has a 99 percent chance of conceiving a baby of a desired sex. However, it comes with a steep price according to AdvancedFertility, the average cost of one IVF round with a PGT test costs approximately $15,500.

According to U.K. law, however, testing an embryo for the purposes of sex selection was made illegal by the Human Fertilisation and Embryology Act 2008. As such, the only legal way parents can use a PGT-A test and IVF to select the sex of a baby in the U.K. is by proving that there are significant genetic anomalies associated with the parents having a child of a certain sex.

Dr Evangelia Elenis, chief medical advisor at Tilly and chief physician in obstetrics and gynecology, believes that "the reasoning behind the [Babydust] method makes sense from a theoretical perspective, but not in a practical reality."

"As far as I know, there is no conclusive scientific proof for the Babydust method," she told Newsweek.

Elenis encourages couples to remember that menstrual cycles "are not perfectly regular and calculating averages may not work." Still, she explains that tracking LH levels and predicting ovulation can certainly help in conceiving. However, Elenis warns that so far, "there is no scientific proof that you can control whether a sperm that carries an X or a Y chromosome will fertilize the egg."

Newsweek also spoke to a few members of The Babydust Method Facebook group about their experiences regarding whether or not they were successful and how long and strictly they followed the method.

Earlier this year, Kayla George welcomed a baby boy as a result of a "successful sway" based on the Babydust Method. "We are so thankful for this method," the mother shared.

She described that the "method looked to be the most reliable and cost efficient" compared to other sex selection techniques and methods commonly discussed on the internet. George shared that she and her partner followed the instructions attentively and that it took her two cycles to get a positive test result. As per Taylor's guidance, George tracked her LH levels twice a day for three months prior to trying to conceive.

"We have five wonderful daughters, and we were just hoping to be lucky enough to add a little boy to our family. If we didn't fall pregnant, or if it was another little girl we would have been okay," she shared.

Meanwhile, one woman shared her experience of a "boy sway fail," which happened despite her strictly following all the instructions, tracking her LH levels and even consulting with the author of the book.

Liana Averbeck is currently 18 weeks pregnant with twin girls, after having tried for three months to conceive a baby boy using the Babydust method.

"All details were discussed with the author and she deemed the sway a perfect boy sway," she shared.

According to Averbeck, she even tracked her body basal temperature (BBT) so as to ensure an accurate prediction of her ovulation in addition to charting her LH levels twice a day.

Regardless, although at first she felt "a little bit of a loss and sadness for not getting one boy," the woman has no regrets: "Using this method, I felt I was learning more about my body and was more confident in conceiving," she told Newsweek. Now, Averbeck described that she feels "blessed" to be pregnant with her baby girl twins.

The woman suspected that the genetics on her husband's side might have played a role as she shared that he "mostly has girls on both sides of the family."

Averbeck also said that she discourages the method "if you cannot bear a 'gender sway fail' and would not want another baby of the same gender."

Originally posted here:
How Parents 'Guarantee' Baby's Gender' Using the Babydust Conception Hack - Newsweek

Recommendation and review posted by Bethany Smith

The conservative ‘What is a woman?’ talking point, explained – The Week

July 17th, 2022

In the wake of the Supreme Court overturning Roe v. Wade, the 1973 decision that established a constitutional right to abortion, a parallel debate has erupted over the use of inclusive pregnancy language. Critics say "omitting the word 'women' to make room for the relatively tiny number of transgender men and people identifying as nonbinary who retain aspects of female biological function and can conceive, give birth, or breastfeed" effectively "erases" women, while supporters of inclusive language call that argument "transphobic" and argue that using such terms "costs us nothing and makes the movement stronger."

Nevertheless, conservatives have weaponized "gotcha"questions like "What is a woman?" or "Can men get pregnant?" Here's everything you need to know:

In a Senate Judiciary Committee hearing this week,University of California, Berkeley law professor Khiara Bridges went viral after Sen. Josh Hawley (R-Mo.) asked her to clarify if her use of the term "people with the capacity for pregnancy" meant "women." "Many women cis women have the capacity for pregnancy, many cis women do not have the capacity for pregnancy," Bridges answered. "There are also trans men who are capable of pregnancy as well as non-binary people who are capable of pregnancy." She went on claim that Hawley's "line of questioning" was "transphobic" and "opens up trans people to violence."

Hawley's question did not come out of a vacuum, however. Right-wingers like conservative podcast host Matt Walsh and theconservative Christian YouTube channel What Would You Sayhave been using the "gotcha" question "what is a woman?" for a few years now, both to troll liberals but also in higher stakes encounters.Sen. Marsha Blackburn (R-Tenn.), for example, asked then-Supreme Court nominee Ketanji Brown Jackson to "provide a definition for the word 'woman'" during her Senate confirmation hearing earlier this year (Jackson ultimately responded that she could not because she is "not a biologist").

Questioning gender is as old as civilization itself. Letters from the 18th century B.C. discovered in Mari, Syria, describe a type of prophet known as an assinn or "man-woman." Historian Edward Gibbon wrote that the teenage Roman Emperor Elagabalus "cop[ied] the manners and dress of the female sex." Court documents from the late 1300s record the interrogation of London prostitute Eleanor Rykener, who confessed to having previously lived as a man under the name "John." More recently, gender critics have argued that while we tend to think of our definition of "woman" as beingthe objective definition, it isn't; it's culturally constructed.

But the question of defining "women" has become particularly seized upon by Republicans since the Roe v. Wadedecision. "Turning their ire on inclusive language is a conscious strategy," argues Vox. "It allows Republicans to misrepresent and minimize the effects of laws like abortion bans, by omitting groups that they affect. Engaging in transphobia also plays well withsome members of the Republican base."

The opposite of a "constructionist" definition of gender would be an "essentialist" definition, one rooted in female biology: "Previously a commonly understood term for half the world's population, the word had a specific meaning tied to genetics, biology, history, politics, and culture," wrote New York Times columnist Pamela Paul in a recent op-ed. "No longer. In its place are unwieldy terms like 'pregnant people,' 'menstruators,' and 'bodies with vaginas.'" Or assoon-to-be-former Rep. Madison Cawthorn (R-N.C.) put it a "woman" is "XX chromosomes, no tallywhacker."

Before they ever reached into congressional hearings and cable news, the debate between these two definitions of womanhood played out in the left-leaning milieus of academia and feminist activism, with "gender critical" feminists labeled "trans-exclusionary radical feminists" or TERFs by their detractors arguing in favor of essentialism. Now the issue has become front and center, as stoked by the "remarkable bad faith" questioning of conservatives, Philip Bump wrote for The Washington Post.

Others, though, argue the whole debate has become a distraction."The truth is, you can be kind. You can be inclusive. You can also be accurate," writer andphilosopher Kate Manne wrote in a recent Substack post pushing back on the circular debate. "You may just have to make a small but necessary moral effort. And, if you are not prepared to do that, you should be corrected when applicable and subject to due criticism. That is not cancellation, to anticipate. It is basic accountability."

Read more:
The conservative 'What is a woman?' talking point, explained - The Week

Recommendation and review posted by Bethany Smith

Beard Growth: Tips to Speed Up the Process – Medical News Today

July 17th, 2022

Although exercising and eating a nutritious diet may speed up beard growth, the main factors that determine how fully a persons beard will grow are hormones and genetics.

Males start to grow facial hair during puberty. Many of them will notice that their facial hair first begins to grow on the upper lip.

Other areas people may notice early facial hair growth include the chin or the sides of the face near the ears, which people refer to as sideburns.

Facial hair grows differently for everyone. Some individuals may be able to grow a full beard during late stage or even middle stage adolescence. Others may continue to have sparse areas of growth until their late 20s, while some may never experience significant facial hair growth.

This article will explore what factors influence a persons beard growth and whether it is possible for someone to make their beard grow faster.

Genetics and hormones are the main factors that determine how quickly and fully a persons beard will grow. Their lifestyle and habits may also affect how their beard grows.

Testosterone is a hormone that affects the growth of facial hair, and its levels can vary. Males between 19 and 38 typically have a range of 264 to 916 nanograms per deciliter. This represents the 2.5th to 97.5th percentile for testosterone.

Low testosterone can adversely affect beard growth. For males with low testosterone, taking supplements under a doctors supervision may help increase beard growth.

If a persons testosterone levels fall within typical ranges, taking supplements will most likely not affect their beard growth.

Genetics also affect the way a persons beard grows. Some genes make them more prone to growing a fuller beard, while others may only ever be able to grow a sparse or patchy beard or other facial hair.

The health and well-being of a person affect how their whole body functions, including how their beard grows. Even though it is not possible to alter someones genes, lifestyle habits they can adopt may help them achieve a fuller beard.

Exercise improves blood flow, which helps stimulate hair follicle growth. Exercises, such as weightlifting and strength training, may also help boost a persons testosterone levels.

During the day, testosterone levels naturally fluctuate in young males, with a higher level in the morning and a lower level in the afternoon.

Good nutrition from eating a balanced diet may help in growing a beard and staying healthy.

According to a 2015 study, obesity and low testosterone have a bidirectional relationship, meaning that low testosterone can lead to obesity and obesity can lead to low testosterone.

Nutrients, such as zinc, may also be beneficial for testosterone levels. A nutritious diet will not override genetics, but it may help the existing hair grow healthier and fuller. Some foods that can help include:

Some supplements can contribute toward maintaining a persons health in a way that is conducive to growing their beard as fully as their genetic makeup will allow.

A person may wish to take a multivitamin containing iron and zinc if their diet does not provide them with sufficient amounts of these nutrients.

However, there are no supplements that will enable a person to grow a beard if they do not have the genes to do so.

Maintaining a healthy skin care routine, including keeping the beard clean, can positively affect how a persons beard will grow and look.

Exfoliating the face can help remove dead skin cells and debris from around each hair follicle, allowing the hair to grow through the skin unimpeded. Exfoliating can also reduce ingrown hairs under the beard.

Leave-in conditioners for beards can nourish the hair and keep it moisturized. This helps reduce and prevent beard dandruff and makes the beard look fuller. It is best to perform a patch test to find out which products work best for the beard.

As well as being necessary for overall health, sleep can also aid beard growth.

The testosterone levels in males generally increase when they are asleep. A 2015 study found that reducing the amount of daily sleep lowered testosterone levels in healthy young males.

Keeping a beard clean and moisturized can help it appear thicker. However, there is no certain routine with scientific backing that can thicken a growing beard.

However, some anecdotal evidence suggests that olive oil and avocado oil could thicken beards.

It is possible that these may work the way leave-in conditioners do by keeping the beard nourished and moisturized.

Growing a beard depends mostly on a persons genetics.

However, testosterone plays some role in determining how fast and well someones beard will grow.

Making sure to keep testosterone levels within a stable, healthy range by regularly exercising, eating well, getting sufficient, restful sleep, and exfoliating can help a persons beard grow as thick and full as it is naturally able.

Go here to see the original:
Beard Growth: Tips to Speed Up the Process - Medical News Today

Recommendation and review posted by Bethany Smith

The canine behavior of the LGBTQ cabal – Washington Times

July 17th, 2022

OPINION:

This past week, The New York Times published an opinion piece finally admitting that todays LGBTQ cabal of rainbow activists is little more than a misogynistic cult that reduces women to just a mix of body parts and gender stereotypes.

Writing for the Times, columnist Pamela Paul described what she called the fringe lefts misogynist agenda.

The word women, said Ms. Paul, which has, for millennia, been commonly understood by all rational thinking people to denote genetics, physiology, biology and the basic reality of human existence, is now verboten. In place of this word, we now have nonsensical terms that reduce females to their biological functions; words like pregnant people, birthing persons, menstruators and bodies with vaginas.

This logically strained nomenclature has been force-fed to the American public, bemoaned Ms. Paul, as she cited President Bidens cultural lunacy of removing biological sex from the federal register and replacing words such as mothers and women with birthing people and breastfeeders instead.

Women didnt fight this long and this hard only to be told we couldnt call ourselves women anymore. This isnt just a semantic issue; its also a question of moral harm, an affront to our very sense of ourselves, she concluded.

Amen! Welcome to the side of sanity, Ms. Paul.

I have said from the very first days of the LGBTQ movement that this broken worldview could only have one logical end: the complete degradation of what it means to be a human being and that women would be the first to suffer at the hands of this grand lie.

You cant dumb down human identity to nothing but the sum total of human inclinations and retain any modicum of human dignity. If we define ourselves by our subjective desires and not by Gods objective design, our ontology the reality of who we are becomes meaningless, and being a woman means absolutely nothing.

Think about it.

Today our schools teach our youngest girls that women arent real. Our Congress tells women they have no right to their own restrooms, sports or showers. Our corporations proudly defend the cultural appropriation of women by dysphoric men who want to act like something they are not. And todays feminists now pretend a female is a fabrication rather than a biological fact.

The question we should all be asking is this: What could possibly be more degrading than publicly supporting the blackfacing of women in a manner that is just as cartoonish and insulting as it is when white people dress up in literal blackface to mimic and mock people of color?

This is misogynistic. It diminishes the woman to little more than a delusion. It disregards who she truly is. It elevates feelings over facts. It supersedes the rational by supplanting it with the emotional. Moreover, it replaces the reality of the female with the fantasy of those who seek to use her for political gain.

All of this is little more than a placard for a culture a cult of deception and deceit. Its a snapshot of a people who have literally lost their minds.

When your definition of the person becomes little more than the cumulative effect of his or her sexual urges, you are admitting you think those with a given appetite are actually defined by that desire. With a not-so-thinly disguised bigotry, you are saying you think thats just who they are and that their personal identity is nothing more than the totality of their libidinous inclinations. Is this not the ultimate insult to your fellow man? Is this not the grandest slur of what it means to be a woman?

The biblical model is the opposite. It elevates men and women to the highest status of all worldviews. Genesis, as well as all the rest of scripture, tells us we are the imago Dei, not the imago dog. We are made in the image of God, not the image of the animal. We are not defined by our cravings but by our creator. Ultimate meaning comes from our Lord, not our libido. We have objective identity, dignity and worth. Gods reality always trumps human emotions and passions; mine, yours, and the governments.

This is the good news of the Gospel. Christ, himself makes it clear that, on this issue, Ms. Paul is right. No one is just a mix of body parts and gender stereotypes. Women are made in the image of God, and that image cannot be manipulated, coopted or changed by a bunch of delusional sexual activists bent on denying reality and acting like dogs.

Everett Piper (dreverettpiper.com, @dreverettpiper), a columnist for The Washington Times, is a former university president and radio host. He is the author of Not a Daycare: The Devastating Consequences of Abandoning Truth (Regnery).

Read the original:
The canine behavior of the LGBTQ cabal - Washington Times

Recommendation and review posted by Bethany Smith

Why Are We All So Obsessed With Celebrity Plastic Surgery? – HuffPost UK

July 17th, 2022

Youre on TikTok scrolling, as you do and have been for the past 45 minutes. Youve watched a dozen make-up tutorials, Love Island recaps and videos of cats doing very cat things when you stumble on a video of Kendall Jenner.

But its not a clip from Keeping Up With The Kardashians or even Kendall modelling on a runway. Its of her face being analysed by a surgeon. You watch as a doctor tells you what surgery she has or hasnt had. Theyll tell you that shes got fillers in her lips, botox and a secret rhinoplasty (aka nose job).

Click through to the doctors page and suddenly youve entered a world of celebrity plastic surgery videos. Theres been a surge of these videos emerging on my for you page in the past couple of months. The hashtag #plasticsurgery have 13.3 billion views, while the hashtag #celebrityface has 1.6 billion views.

When I typed, Has Kendall Jenner had plastic surgery? into my search bar, hundreds of videos came up. Some from cosmetic professionals, others from regular users, all picking apart her face. Its no surprise these videos mainly analyse women. Celebs such as Ariana Grande, Selena Gomez, Khloe Kardashian and Zendaya are also being facially examined on the daily.

Even teenagers like Stranger Things Millie Bobby Brown, 18, are scrutinised on TikTok though one in-depth blog about her face allows the changes that people are nitpicking on might be just her growing up and better makeup.

So, why are these clips so popular? It could be that celebrities dont often disclose what work theyve had done leaving their fans to guesswork.

When supermodel Bella Hadid, 25, shared that she had got a nose job at 14, few were surprised. Wed seen the before and after pictures, knew she had the money to pay for surgery, so people werent shocked to hear it confirmed.

However, speculation around a celebs face is often just that: speculation.

Earlier this year, the pop star Doja Cat publicly called out YouTuber Lorry Hillmade for making a video claiming the singer had got a nose job. Hillmade has plastic surgery herself and uses her page to dissect celebritiess faces to spot if theyve also had work done.

But Doja Cat wasnt happy about it and went on Instagram Live to say so. Im upset because theres lies about me, the singer said.

Dr Tunc Tiryaki, a consultant plastic surgeon at the Cadogan Clinic in London, doesnt think the videos are the root of the issue. Instead, he points the finger at those in the public eye who arent honest about the work theyve had done.

Id say the problem is more with celebrities who get liposuction, for example, but claim to get these results with diets, he says. Or celebrities who have had a face lift but say they had a thread lift [which is] similar to a face-lift but less invasive and cheaper.

By doing this, he says, celebrities are creating a huge false expectation, one that can make their followers compare themselves to someone with much greater means whose face is the result of thousands of pounds worth of surgery rather than more affordable tweakments, good makeup or basic genetics.

Secondly, these videos undermine the accurate results of surgery, especially surgical interventions, he says. People are coming to me expecting huge results because a celebrity has lied about what procedure theyve had.

This is dangerous, Dr Tiryaki, says, especially when it comes to filler and botox, as there isnt an age restrictions on these non-surgical procedures, nor is the industry properly regulated.

The rate of complications of fillers are rocketing, he says. This is partially because its easy to do and fillers can be done not only by dermatologists and plastic surgeons but anybody.

Group4 Studio via Getty Images

Many of these videos are made my cosmetic doctors, but even a surgeon wont be able to tell you if a celeb has had work done unless the professional did it themselves, says Dr Tiryaki, who warns against trusting these opinions. I think deep research is needed as its hard to fight against false information, he says.

And while there is an audience for these videos, people will continue churning them out. So, why do the general public enjoy these videos so much?

Many comments under the line highlight the relief some people feel when they discover their favourite celebs has had a bit of filler. So Im not ugly, Im just poor, one user writes. Given the online world and its facade of perfection, perhaps these pages do serve a purpose by highlighting why we shouldnt be comparing ourselves to celebrities.

Federica Rosso, a clinical psychologist at the mental health organisation Therapethical, believes the content is popular, because it can make people feel better about themselves even if that effect is short-lived.

People might start thinking that perfection per se does not exist. Even if they see themselves as not perfect in the mirror, they realise that one attractive celebrity did [the same] at some point and went through surgery, she says.

It creates an escape option from their awful feeling that is, in fact, a coping mechanism.

However, it can also encourage people to get work done that may not be in the best interests of their health or their finances. The problem with these videos is that theyre reinforcing a narrative that says we could achieve similar results if only we were willing to go under the knife ourselves. says Rosso.

We might start to wonder if our faces are ugly or unattractive or if there are parts of our bodies that need fixing. This can lead us down a dangerous path of body dysmorphia and eating disorders, both of which lead people down an unhealthy path toward self-harm and suicide.

These videos can be triggering for the celebrities they feature, too and, whether or not they have had any surgery, make them very self-critical of their looks.

Seeing themselves on these types of sites can be like a slap in the face, says Rosso. Theyre constantly reminded of their flaws and failures, even if theyre not real.

And this is nothing new. Dirty Dancing star Jennifer Grey, 62, has spoken openly about the nose job she had in the wake of that movies success, which not only ruined her career, but became the dominant narrative of her life.

Meanwhile, in 2016, Rene Zellwegger responded to claims shed had surgery on her eyes with an open letter in HuffPost, headlined We Can Do Better.

Its no secret a womans worth has historically been measured by her appearance, Zellwegger, now 52, wrote. The double standard used to diminish our contributions remains, and is perpetuated by the negative conversation which enters our consciousness every day as snark entertainment.

She added: The resulting message is problematic for younger generations and impressionable minds, and undoubtably triggers myriad subsequent issues regarding conformity, prejudice, equality, self acceptance, bullying and health.

So, should we continue to click on these videos? The answer surely lies in being honest with yourself about why youre watching them. Yes, they can serve as a reminder that the tweaked and filtered faces we see online every day arent real.

However, lets all remember that the people behind them very much are.

Read the original post:
Why Are We All So Obsessed With Celebrity Plastic Surgery? - HuffPost UK

Recommendation and review posted by Bethany Smith